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The term “Mitochondrial Disease” (MD) coins a group of genetic disorders caused
by dysfunctional mitochondria: the organelles that generate energy for the cells. 
Mitochondria are present in every cell of the human body (except for red blood cells)
and convert the energy of nutrients into adenosine triphosphate (ATP) through oxidative
phosphorylation (OXPHOS). MDs are the most prevalent inherited metabolic disorders,
with an incidence of approximately 1:5000 live births [1]. MDs are heterogeneous, multi
systemic and progressive in nature and may present from infancy to adulthood with a 
severity ranging from severe during early childhood to a milder phenotype later in life. 
Tissues with a high energy need, such as the brain, skeletal muscle and heart, are most 
commonly and severely affected. Maternally Inherited Diabetes and Deafness (MIDD),
Mitochondrial Myopathy (MM), and Chronic Progressive External Ophthalmoplegia 
(CPEO) are the most frequent reported phenotypes in adult patients [2]. Mitochondrial
dysfunction can result from mutations in either nuclear DNA or mitochondrial DNA. 
For mitochondrial DNA mutations the percentage of affected mitochondria per cell in 
widely between tissues of a single individual. This marked intra-individual and inter-
individual variation in mitochondrial heteroplasmy (partially) explains the wide spectrum
of diseases and disease severity that can be observed between family members that 
carry the same mitochondrial mutation. Mitochondrial DNA mutations have maternal
inheritance. With the most frequently reported pathogenic type in adults being the 
m.3243A>G point mutation [2, 3].
The mitochondrial 3243A>G mutation
The m.3243A>G mutation is commonly described as the MELAS mutation. The acronym
Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes. In
1990 the m.3243A>G mutation was found as the molecular basis behind this patient
entity [5, 6]. The phenotype Maternally Inherited Diabetes Deafness (MIDD) is also
caused by this same mutation and is much more frequent [7]. Other phenotypic 
expressions of the m.3243A>G mutation include mitochondrial myopathy, hypertrophic
cardiomyopathy [8], retinal dystrophy [9], focal segmental glomerulosclerosis [10], 
acronym MELAS. [12, 13] In the Radboud Centre for Mitochondrial Medicine (RCMM) 
there is a well-documented cohort of 151 m.3243A>G carriers who are followed in the
natural disease course study [14]. The overall progression of disease in carriers of the





a shortage and/or disbalance of nutrient intake that leads to negative changes in body 
shortage in MD is malnutrition on a cellular level. Malnutrition is a complex problem and 
present, and both are known to occur in MD patients [16, 17]. The combination of low 
muscle mass and low muscle strength seen in malnourished MD patients may also be
Figure 1. Malnutrition according to Stratton [15].
Body composition is known to be important for physical functioning in the general 
population and even more in neuromuscular disorders [20-23]. Altered body composition 
in MD patients has been reported [17, 24] and a higher skeletal muscle mass index in 
these patients was correlated with higher muscle strength [24]. The low physical 
functioning in MD patients may also be related to alterations in both nutritional intake
and nutritional status. Recent observational studies suggested that MD patients have 
inadequate protein intake and are at risk of malnutrition [17, 25]. This could affect both 
body composition and physical functioning. The physical functioning of MD patients 
appears to be determined by the availability of energy (ATP) on the one hand and the 
nutritional status on the other. The assumed relationship between these is summarized
in Figure 2.
It is suggested that malnutrition may worsen symptoms in MD, as for instance was shown 
in a study in young MD patients in which an association between nutritional status and
mitochondrial functioning was observed [26]. Vice versa, it is known from other diseases
such as anorexia nervosa [27] or cancer cachexia [28, 29] that malnutrition per se causes 
secondary mitochondrial dysfunction. From data of children with mitochondrial disorders 
it was suggested that by improving the nutritional status in MD patients, ATP production
may be improved [30].
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Figure 2. Assumed relationship between body composition, nutritional intake and physical functioning 
in patients with MD.
Knowledge gap
At this point there is no proof that the presumed associations in Figure 2 do exist, also
data on the incidence of malnutrition and sarcopenia in the adult MD population are 
lacking.
Nutritional Assessment
Nutritional assessment entails the systematic assessment of nutritional status and 
nutritional needs. Measurements are performed in a structured (subjective and
objective) manner that can be categorized into three domains:
1. Food intake and requirements
2. Body composition
3. Functional parameters
Nutritional assessment is part of every dietary consultation and is essential in dietary
diagnostics and -research. The individual dietary treatment plan is based on data from 
the nutritional assessment. Nutritional assessment as such can be performed on many
levels, ranging from very basic to more sophisticated (and accurate) assessments. 
Basics for example comprise an assessment of dietary history regarding food intake,
anthropometry (height and weight measurements) for body composition and interview 
data for functioning. “More accurate” also implies more time consuming, expensive and 
invasive tests for patients. In striving for the best possible individual dietary treatment 
options dietitians search for the optimal balance between intensive assessment methods
and obtaining reliable data to design the individual treatment plan.
Diagnosing malnutrition in MD patients is challenging [17, 31] since standard screening






Because of the very heterogenous phenotypical character of the MD patient population
recent literature suggests to perform nutritional assessment to determine the nutritional
status [17, 25], yet the most optimal techniques, and the cutoff values in MD are unknown.
Interventions
Until now, no effective treatment for MD is available. Current treatment strategies focus 
on symptom relief, securing physical functioning and quality of life [3]. It is known that 
dysphagia, fatigue, diabetes and epilepsy [3]. Therefore, in daily practice many nutritional 
interventions are already common in MD but the evidence to support these interventions 
is scarce. Examples of such interventions include the ketogenic diet and various vitamin 
The Radboud Center for Mitochondrial Medicine (RCMM) has expertise in MDs in 
general and with individual dietary interventions.
Some of the normal symptom-based interventions that seem effective for other patient
categories fail in these patients. For example, it is common in patients with dysphagia to
advice thickened liquids. This strategy does not work in MD patients because consuming 
the thickened liquids requires more energy and leads to fatigue-induced swallowing 
problems. The evidence of this and similar advises are lacking in the literature so far.
on the clinical outcome in the setting of MD, due to the small number of patients and
the heterogeneous nature of the population [38]. Therefore, a personalized intervention
approach in these patients might be more appropriate.
Knowledge gap
Adequate data on the frequency of dysphagia and gastrointestinal problems and their
association with malnutrition in MD patients is lacking so far. The same applies for 
evidence on personalized nutritional interventions based on nutritional assessment 




AIM OF THIS THESIS
The overall aim of this thesis is to improve the knowledge on nutrition-related issues in 
MD and thereby improve the functioning and quality of life in adult MD patients.
To this end tree goals are formulated (Figure 3):
1. To gain knowledge on the nutritional status and its determinants in adult MD patients.
3. To provide evidence for individually tailored nutritional interventions in MD patients.
Figure 3. Research aims of this thesis.
APPROACH AND OUTLINE OF THE THESIS
Part 1 focuses on Nutritional Assessment in adult MD patients.
Chapter 2 is an observational study that explores the frequency and severity of 
gastrointestinal complaints in 92 adult patients carrying the m.3243A>G mutation 
using a validated questionnaire. Data were compared with those obtained in healthy
controls. Furthermore, the association between symptoms, disease severity and the risk 
for malnutrition and BMI was assessed. 
Chapter 3
this observational, cross-sectional, retrospective study, 60 three-day nutrition diaries
of adult MD patients were analysed and compared with the Dutch recommended daily 
allowance and the Dutch National Food Consumption Survey.
Chapter 4 comprises the results of the DYNAMO1 study. This study focuses on the 
associations between physical functioning of MD patients and the alterations in body 
composition and protein intake (Figure 2). Also, the occurrence of malnutrition and
sarcopenia was assessed. Importantly, in this 2-site cross-sectional study, genetically 
proven adult MD patients were age-, body mass index-, and gender-matched to controls.





Chapter 5 aimed to identify the optimal method to estimate total energy expenditure in 
MD patients. Resting energy expenditure was measured in adult MD patients carrying
the m.3243A>G mutation using indirect calorimetry and compared with results of 21
predictive equations for resting energy expenditure, as well as with indirect calorimetry
data in healthy controls. Physical activity level (PAL) was assessed using accelerometery 
(SenseWear®
estimated activity levels. Measured total energy expenditure was compared with usual
care and energy recommendations for healthy adults.
Part 2 focuses on Nutritional Interventions in adult MD patients. 
Chapter 6 describes the results of the DINAMITE2 study. The aim of this randomized
controlled trial was to explore the effect of an individually tailored dietary intervention 
on personalized goals, body composition, functioning, and quality of life in 39 adult MD 
patients due to the m.3243A>G mutation. The intervention group (n = 20) received 
an individually tailored dietary intervention over a 6-month period, whereas controls
(n = 19) received standard care during 6-months (control period), followed by an 
individually tailored dietary intervention for the next 6 months (intervention period). 
Nutritional assessment and QoL measurements were performed at 3-month intervals.
Chapter 7 
in genetically proven MD patients (both paediatric and adults).
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Previous research has shown that dysphagia and gastrointestinal problems occur 
frequently in carriers of the m.3243A>G mutation, however the exact frequency and 
severity have not been determined. We hypothesize that adult carriers have an increased 
risk for malnutrition.
Methods
In this observational study we evaluated the presence of gastrointestinal problems
and dysphagia in 92 carriers of the m.3243A>G mutation. The severity of the general 
Scale (NMDAS). Gastrointestinal involvement, dysphagia and the risk for malnutrition
were scored using the Gastrointestinal Symptoms Questionnaire and The Malnutrition
Universal Screening Tool. Gastrointestinal symptoms and anthropometrics were
compared to healthy controls.
Results
Our results show that height, weight and BMI of these carriers were lower than the
national average (p<0.05). Seventy-nine carriers (86%) suffered from at least one 
cause more problems than liquids. A negative correlation between BMI and heteroplasmy
levels in urinary epithelial cells (UEC) was present (spearman c.c.= - 0,319, p= 0,003).
Conclusion
Dysphagia and gastrointestinal problems, especially constipation are common complaints 
in the total m.3243A>G carriers cohort and are not related to heteroplasmy levels in UEC 
or disease severity. The severity of gastrointestinal problems as well as overall disease
severity is associated with an increased risk for malnutrition.
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INTRODUCTION
Mitochondria and the m.3243A>G mutation
Mitochondrial diseases are the most prevalent inherited metabolic diseases, with an
incidence of approximately 1:5000 live births [1]. Mitochondria are the cellular organelles 
responsible for oxidative phosphorylation, which produces energy in the form of 
adenosine triphosphate. This process is accomplished by the four complexes (complex 
I-IV) of the respiratory chain and F1-F0 ATP synthase. Mitochondrial dysfunction can
result from mutations in either nuclear DNA (nDNA) or mitochondrial DNA (mtDNA).
patients with Mitochondrial myopathy, Encephalopathy, Lactic Acidosis and Stroke-like
episodes. In 1990 the m.3243A>G mutation was found as the molecular basis of this 
disease [3, 4]. The mutation is located in the MT-TL1 gene and is the most common 
pathogenic mitochondrial mutation [5-7], commonly described as the MELAS mutation.
The phenotype maternally inherited diabetes deafness (MIDD) is also caused by this 
same mutation and is much more frequent [8] Other phenotypic expressions of the
m.3243A>G mutation include hypertrophic cardiomyopathy [9], retinal dystrophy [10],
and oligo-symptomatic variants of the acronym MELAS [13, 14]. The percentage of 
level of heteroplasmy may vary widely between tissues of a single individual. This marked 
intra-individual and inter-individual variation in mitochondrial heteroplasmy (partially)
explains why there is a wide spectrum of diseases and disease severity observed between
family members that carry the same mitochondrial mutation. Previous studies have 
shown that urinary epithelial cells (UEC) are the best non-invasively available tissue to 
test the level of heteroplasmy of the m.3243A>G mutation [15, 16].
Gastrointestinal involvement in m.3243A>G carriers
Dysphagia and gastrointestinal problems occur frequently in mitochondrial patients,
including patients carrying the m.3243A>G mutation [17-19]. However, the exact 
frequency and severity of these symptoms have not been determined. In a population
study of carriers of the m.3243A>G mutation, 61% of the subjects had gastrointestinal
complaints. These were, after hearing loss, the most frequently reported symptoms of the
m.3243A>G mutation using the Newcastle Mitochondrial Disease Adult Scale (NMDAS)
Previously in a small cohort of MIDD patients, a high prevalence of constipation and/or 
diarrhea (88%) was found [21]. Severe gastrointestinal problems like the pseudo obstruction
syndrome, surgery-requiring constipation and pancreatitis have been described in patients
carrying the m.3243A>G mutation, although the incidence in these patients remains
unclear [18, 21]. Gastrointestinal problems are frequently reported in healthy controls 
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as well [22], and so far, studies comparing the frequency and severity of gastrointestinal
problems in patients with a mitochondrial disease and healthy controls are lacking.
Dysphagia in mitochondrial disease has been described in several studies which are
the m.3243A>G mutation, incidences vary from 18% in a study using the NMDAS to 
Also, short stature and lower bodyweight are frequently described in mitochondrial 
disease. Patients with a MIDD phenotype have lower body mass index (BMI, weight(kg)2/
height(m)) compared to other diabetic patients [25-27].
For both dysphagia and gastrointestinal problems, a relation with lower body weight 
and risk for malnutrition in patients with a mitochondrial disease has been suggested
but never proven [18, 21]. The present study therefore focused on dysphagia and 
gastrointestinal problems in a cohort of carriers of the m.3243A>G mutation and 
MATERIALS AND METHODS
Patients
At the Nijmegen Center for Mitochondrial Disorders (www.ncmd.nl) at Radboud
university medical centre 114 adult carriers of the m.3243A>G mutation participate 
in our cohort study [24]. All participants received the questionnaire. This study was 
approved by the ethics committee of the Nijmegen-Arnhem region. Written informed
consent according to the Helsinki agreement was obtained from all carriers.
General symptoms
All carriers were scored using the NMDAS [28]. The NMDAS constitutes a validated 
method to monitor the clinical expression of mitochondrial disease and to follow-up
Current function, which gives insight into the general functioning of patients in past four 
i.e. a general and neurological clinical examination, which gives insight in the current
SF-12v2 quality of life test.
Gastrointestinal symptoms evaluation
All participants received the Gastrointestinal Symptoms Questionnaire [29, 30]. This 
self-report questionnaire contains 16 items regarding gastrointestinal involvement 
25
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of disease for the past four weeks. Severity of the symptoms is scored on a 7-point
likert scale, where 0 resembles no symptoms and 6 resembles extreme symptoms. The 
of stools. The validated Malnutrition Universal Screening Tool (MUST) [31] was used to
collect the self-reported anthropometric data and to screen for the risk for malnutrition. 
We compared the data to age matched anthropometric data from the Dutch Central
Bureau of Statistics (CBS) 2011 (n= 2034) and to a Dutch reference database form the
Gastrointestinal Symptoms Questionnaire (n=1616). Data collection for this reference
database was done in 2006 participants who matched the general Dutch population 
were selected with CBS statistics [22].
Mutation Analysis
Heteroplasmy levels of the m3243A>G mutation were determined in UEC in all
participants using Pyrosequencing TM technology (Pyrosequencing, Uppsala, Sweden)
as earlier described [11]. The pyro sequence reaction of the m.3234A>G mutation had a
precision of 1,5%, and the mutation was detected from a heteroplasmy level of 5%. The
detection limit for the mutation was determined by serial dilution of a sample containing 
this mutation with wild type mtDNA.
Statistics
We used descriptive statistics to present the heteroplasmy levels in our patients.
the different variables in relation to BMI and gastrointestinal complaints Independent 
samples T-test was used. We corrected for multiple testing using the Bonferroni test. 
evaluate the relationship between heteroplasmy in UEC, gastrointestinal problems, and 
BMI. We used the pearson chi-square to compare BMI category for males and females 
and carriers with healthy controls.
RESULTS
General patient characteristics and anthropometrics
Data were collected from September to November 2011. From 114 questionnaires
that were sent out, 92 were returned (81% response rate). Of these 92 patients 68% 
(n=63) were female. Mean age was 45 years (±14.3). In the Gastrointestinal Symptoms 
Questionnaire database Mean age was 52.3 ± 17.2, 66% (n=1067) were female.
Mean NMDAS score was 15.7 (±10.9) range 0-56 and average heteroplasmy level in UEC
was 50% (range 5%-98%). Thirty-eight patients (41%) were diagnosed with diabetes, of
26
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whom 22 (24%) used insulin. Hearing loss was reported by 59 patients (64%), 27 patients
(5.4%) suffered from epilepsy and two (2.2%) had had stroke like episodes in the past year.
Table 1. Anthropometrics in male and female m.3243A>G carriers and healthy 40-50 years old 
Dutch controls.
m.3243A>G Healthy P value
Height men (cm) 178.4 (±6.9) 180.9 (± 7.9) 0.1
Height women (cm) 164.8 (± 8.3) 167.5 (±7.1) 0.004 *
Weight men (kg) 75.8 (±12.8) 84 (±12.8) 0.002 *
Weight women (kg) 65.2 (±17.7) 70 (±12.8) 0.005 *
BMI men (kg/m2) 23.8 (±3.6) 25.6 (± 5.4) 0.08
BMI women (kg/m2) 23.9 (±6) 24.6 (± 8.4) 0.5
BMI category 0.00 *
Overweight or obesity: BMI >25 n (%) men 11 (37) 588 (59.9)
Overweight or obesity: BMI >25 n (%) women 19 (30) 444 (42.2)
Healthy weight: BMI 20-25 n (%) men 16 (53) 391 (39.9)
Healthy weight: BMI 20-25 n (%) women 34 (54) 595 (56.5)
Low BMI < 20 n (%) men 3 (10) 2 (0.2)
Low BMI < 20 n (%) women 10 (16) 14 (1.3)
*P=<0.05
Female carriers were 2.7 cm shorter (average 164.8 cm versus 167.5 in healthy p= 0.004) 
carriers and healthy controls (average 178.4 m versus 180.9 in healthy controls p= 0.099) 
(Table 1). Male subjects weighed 8.2 kg less than controls (75.8 versus 84 kg p= 0.002) 
and females weighed 4.8 kg less (65.2 versus 70 kg p= 0.005).
Figure 1. Body mass index in male and female m.3243A>G carriers and healthy Dutch controls.
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2) or obesity 
(BMI>30 kg/m2) (32%) compared to the average Dutch population (48%) (Figure 1).
2) than the average
Dutch population: 14% versus 2%. Of the women with a NMDAS score above 20, 31%
were underweight. Carriers with BMI <20 kg/m2
(p=0.01). A negative correlation between BMI and heteroplasmy levels in UEC was 
present in carriers of the m.3243A>G mutation (spearman c.c.= -0.319, p= 0.003).
Nineteen percent (n=17) of the carriers had a MUST score of 1 or 2: average (12%) 
to high (7%) risk for malnutrition. In 14 carriers this score was based on their low BMI. 
Of the other 3 carriers with a risk for malnutrition 2 had a healthy weight and one was 
overweight, there MUST scores were based on more than 5% loss of bodyweight in the 
last 6 months.
The majority of carriers (81%) had a MUST score of zero: no risk of malnutrition. Five 
dependent on tube feeding.
Figure 2. Gastrointestinal symptoms in m.3243A>G carriers and healthy Dutch controls.
Gastrointestinal complaints
In the four weeks before answering the questionnaire, 79 carriers (86%) suffered from 
at least one gastrointestinal symptom. Nearly all gastrointestinal complaints had a higher
frequency and increased severity in carriers of the m.3243A>G mutation compared




Hard stools or constipation were reported by respectively 48% and 38% of the carriers,
whereas controls only reported these complaints in respectively 22% en 14% (p<0.001). 
Fourteen percent of the patients used laxatives and 44% had a stool frequency of less 
than once a day.
Overall, 69% of the carriers of the m.3243A>G mutation reported one or more
constipation-related complaint (use of laxatives, stool frequency of < 1 time a day, hard
stools and/or self-reported constipation).
Mean severity score of gastrointestinal problems was 10.7 (± 11.9) range 0-50. Carriers 
higher severity score of gastrointestinal complaints. Patients with postprandial fullness 
Gastrointestinal symptoms that were most frequently reported as severe (5, 6 or 7 on 
severe were regurgitation (8%), post-prandial fullness (9%), belching (10%), dysphagia 
for solids (2%), incomplete stools (8%) and sticky stool (7%).
One patient in this cohort had a pancreatitis in the past, two patients needed surgery
for severe constipation.
There was no correlation between heteroplasmy levels in UEC and gastrointestinal 
complaints. Frequently reported symptoms in patients carrying the m.3243A>G
mutation are myopathy and diabetes. The presence and severity of these symptoms 
Dysphagia
In this study 21% of m.3243A>G carriers had trouble swallowing, as scored by the 
the NMDAS swallowing score in the questionnaire this frequency was much higher: 45%.
Using the Gastrointestinal Symptoms Questionnaire, dysphagia seems to be a frequent
problem (33%), but the severity was not very high (Figure 3). Liquids are less a problem 
have trouble with liquids (p=0.008) as with solids (p<0.001).
to carriers without dysphagia. In six carriers with more severe complaints of trouble with 
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trouble swallowing liquids had an average BMI of 24.1 (±5.5), carriers with such problems
had an average BMI of 20.7 (±3.1) (p=0.046).
Figure 3. Dysphagia in solids and liquids in m.3243A>G carriers and healthy Dutch controls.
DISCUSSION
As there currently is no cure for mitochondrial disease [32], optimizing nutrition and 
treating major complaints such as constipation may be one of the few methods to improve 
quality of life. Because gastrointestinal symptoms are very common in these carriers as 
may be a considerable risk for under-diagnosis of these possibly treatable problems.
of the m.3243A>G mutation. These complaints are common in the total patient cohort and 
are not related to heteroplasmy levels in UEC, disease severity or the presence of diabetes.
The severity of gastrointestinal problems as well as the overall disease severity and 
heteroplasmy levels in UEC are associated with a decreased BMI and an increased risk 
for the development of malnutrition. Strong points of this investigation include the high 
number of enrolled carriers with a homogeneous genetic background, despite the low 
incidence of this disease. Also, the high response rate renders these data highly relevant 
for the guidance and treatment of these carriers.
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The high frequency of gastrointestinal problems has been previously described [17, 18, 
21]. We compared our cohort of 92 carriers of the m.3243A>G mutation with a cohort
of 1627 healthy Dutch controls to identify those gastrointestinal problems that are 
motility problems of the bowel are probably the most frequent symptom: for instance, 
constipation was found in 69% of carriers of the m.3243A>G, i.e. by far higher than in 
healthy controls.
Patients presented with a range of underlying gastrointestinal problems. Some were
diagnosed with irritable bowel syndrome (IBS) prior to the mitochondrial diagnose which 
seems not surprising given the diversity of symptoms. Although nausea, diarrhea and 
alternately solid or loose stools are common in this cohort, similar symptoms occur just 
yet remain potentially treatable.
We show in this study that severe gastrointestinal symptoms increase the risk for 
malnutrition in carriers of the m.3243A>G mutation. Fourteen percent of carriers had 
a BMI of <20 kg/m2 and in more severely affected patients (NDMAS >20) even up to 
31% had a BMI of <20 kg/m2. There was no relevant correlation between gastrointestinal
problems and BMI, indicating that probably several other confounders such as depression 
or fatigue may contribute to the risk for malnutrition. Screening for malnutrition or 
gastrointestinal symptoms can lead to early detection, and hence early treatment of these
problems. Since malnutrition has been related to secondary mitochondrial dysfunction 
[33-35] and may worsen outcomes, like in other disease [36, 37], this remains a major 
concern in these patients.
Dysphagia may well be more common than both doctors and patients realize. In a non-
prevalence of dysphagia was reported. For instance, in our previous study we reported 
an 18% incidence of dysphagia in a cohort of m.3243A>G carriers [24]. In a partly 
overlapping cohort we now found that 45% of patients suffered from dysphagia using a 
A patient-reported incidence of dysphagia of 33% was found using the Gastrointestinal
Symptoms Questionnaire. These differences in reported incidences of dysphagia show 
that the method to diagnose dysphagia is instrumental when assessing its incidence and 
suggests that the NMDAS underestimates this problem.
Dysphagia usually develops slowly and is not severe in most patients, and patients may
differences in BMI between patients with mild dysphagia and without dysphagia were 
found. As with other neuromuscular disorders, solid foods seem to cause more problems
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than liquids [38]. Muscle weakness is the most likely cause for dysphagia in this patient 
group and demands a different treatment strategy than dysphagia from other causes [19, 
38]. For example, in dysphagia due to cerebral damage, it is very common to prescribe 
thickened drinks which will aggravate dysphagia in mitochondrial patients and will take 
more energy to consume.
In this study we used low BMI as a marker for malnutrition. Because it is an easily available 
continue variable suitable for comparison with healthy controls and for statistical
analyses. BMI however is not a validated variable for malnutrition in neuromuscular
disorders and it is known that patients with normal BMI could suffer from low fat free 
mass which is also an important marker for malnutrition. In future studies we would like 
to recommend using body composition as an additional marker.
In conclusion, gastrointestinal problems and dysphagia are common in carriers of the 
m.3243A>G mutation. The severity of the gastrointestinal problems as well as the overall
disease severity is associated with an increased risk for the development of malnutrition. 
The common disease scores used to identify severity of disease in mitochondrial patients, 
treating patients with the m.3243A>G mutation should be aware of this high prevalence 
and should therefore actively ask for gastrointestinal problems to ensure a timely 
treatment of these problems.
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Mitochondrial disease (MD) is a group of disorders caused by dysfunctional mitochondria, 
the organelles that generate energy for the cell. Malnutrition in MD patients may lead 
to increased mitochondrial dysfunction, which may enhance already existing symptoms.
unbalanced food intake and to establish which nutrients and product groups are 
particularly compromised in this patient group.
Methods
In this observational, cross-sectional, retrospective study, sixty 3-day nutrition diaries 
of adult MD patients were analyzed and compared to the Dutch Recommended Daily 
Allowance (DRDA) and to the Dutch national Food survey (DnFs).
Results
from DRDA values except for fat and iron. In particular, protein and calcium intake in MD 
for the overall population. In comparison with DnFs the intake of dairy products and
Conclusions
Our study demonstrates that many patients with MD have an inadequate diet. 
inter-individual differences are high, individual diet counseling is recommended for all 
adult MD patients.
Clinical Relevancy Statement
For MD patients using a healthy adequate diet is of utmost importance because of the 
increased risk for malnutrition, gastrointestinal and metabolic problems, muscle weakness 
and fatigue. We found that patients with MD have an inadequate diet rendering them
because a cure for MDs is lacking and treatment remains symptomatic. Since malnutrition
can be treated, with the promise to improve the quality of life, offering individual diet 
counseling seems a promising treatment option in adult MD patients.
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INTRODUCTION
Mitochondrial disease (MD) is a group of genetic disorders caused by dysfunctional 
mitochondria: the organelles that generate energy for the cells. Mitochondria are present
in every cell of the human body - except red blood cells - and convert the energy of nutrients 
into ATP which powers most cell functions. Tissues that require major amounts of energy, 
such as the brain, skeletal muscle and heart, are most commonly and severely affected.
MD is a heterogeneous, multi systemic and progressive disease. The heterogeneity of 
MD is caused by dualistic genome control by mitochondrial DNA (mtDNA) and nuclear
DNA (nDNA). The mitochondrial 3243A>G mutation is the most frequently reported
genotype. MD may present from infancy to adulthood. Patients can be strongly affected 
and may die at childhood or may present with a milder disease phenotype. Maternally 
Inherited Diabetes and Deafness (MIDD), Mitochondrial Myopathy (MM), and Chronic 
Progressive External Ophthalmoplegia (CPEO) are the most frequent reported
phenotypes in adult patients [1].
MD patients frequently suffer from conditions that may affect nutritional intake 
and metabolism such as gastrointestinal problems, dysphagia, fatigue, or diabetes. 
Accordingly, in a previous study in patients with MD caused by the m3243 A>G mutation 
we showed that 86 percent of patients suffer from one or more chronic gastrointestinal
gastrointestinal problems as well as the overall disease severity was associated with a 
lower BMI [2].
Vice versa, it is known from other diseases such as anorexia [3] or cancer cachexia [4, 
5] that malnutrition per se causes secondary mitochondrial dysfunction. From data of 
children with mitochondrial disorders it was suggested that by improving the nutritional 
status in MD patients ATP production may be improved [6]. MD cannot be cured,
and treatment remains symptomatic with the aim to improve quality of life. However,
malnutrition can be treated, with the promise to improve quality of life, as has been shown 
in other diseases, such as head and neck cancer [7] and COPD [8].
Vitamin B and D, iron and calcium are relevant micronutrients in mitochondrial disorders,
these patients, such as fatigue and muscle pains. Also, these micronutrients play an important 
role in mitochondrial function [9, 10]. Although micronutrient supplementation has been
often discussed as a possible treatment strategy in MD patients, the effects are yet not 
proven [9, 11] In addition, data on intake in MD patients of these micronutrients are lacking.
MD patients often report that they lack energy to prepare and consume healthy meals. 
This may lead to an imbalanced diet with high intake of snacks and sugar. This is a concern, 
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because snacks and sugar have low nutritional value which means that patients with
a normal or high BMI may be malnourished because of inadequate protein and/or
micronutrient intake.
Before designing a proper dietary intervention for MD patients, the malnutrition problem
should be analyzed in detail. Disease related malnutrition according to Stratton [12] is 
a shortage and/or disbalance of nutrients intake leading to negative changes in body 
composition, functioning, and clinical outcome. Malnutrition is a complex problem and 
status of present, and both are known to occur in MD patients.
Furthermore, we analyzed which food groups and nutrients are particularly compromised 
in this patient group. The intake of the MD patients was compared not only with the 
recommended daily allowances but also with the Dutch national Food survey [13].
MATERIALS AND METHODS
In this observational, cross-sectional retrospective study, nutrition diaries of eighty adult
MD patients of > 18 years of age were collected between the start of 2013 and the end
of 2016. All patients were treated at the national expertise center for mitochondrial 
disorders: Radboud Center for Mitochondrial Medicine (www.RCMM.info). Nutrition
diaries were included from patients who gave written informed consent. Patients were 
excluded when the MD was not genetically proven and when food diaries were not
completed for a minimum of three days. The study was approved by the medical Ethics 
Committee of the Arnhem and Nijmegen region.
Patients completed the nutrition diaries after reading written instructions from a
preprinted form. They were instructed to register very accurately all foods and drinks 
that were consumed during three days, preferably two weekdays and one weekend day.
measurements codebook [14]. Calculation procedures including the estimations were
documented in a log for consistency.
Anthropometrics were measured at the outpatient clinic. Height was measured in a 
standing position with a calibrated ruler in cm (Seca®). Weight was measured in kilograms 
on a calibrated electronic scale (Seca®). Information about genotype, phenotype, and
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The nutrition diaries were analyzed according to a standardized procedure. Nutritional 
intake was calculated twice by two independent research dieticians using FoodFigures®
observed between both analyses.
FoodFigures® analyses were made separately on a nutrient and on a food product group 
level. Total daily protein, fat, saturated fat, and carbohydrate were calculated (g/day).
Relevant micronutrients [9] were calculated only if they could be reliably obtained and 
calculated based on a nutrition diary. This was the case for vitamin D, calcium, vitamin
B12, and iron. The calculations were solely based on the nutrition diaries, including 
enteral nutrition but without the micronutrient supplements. The micronutrient 
supplements were being checked and reported separately.
requirement. The energy requirement was calculated using the Harris and Benedict 
equation [15] with a standardized low activity factor of 40%, based on previous actometre
measurements in this patient population [16]. Protein intake was compared with the 
standard recommendation for healthy adults of 0.8 g/kg. For protein we calculated the 
requirements with body mass, and a correction for weight was applied in patients with a
BMI outside the healthy range. Weight was corrected to a BMI of 20 kg/m2 for patients
with a BMI below 20 kg/m2. For a BMI > 30 kg/m2, weight was corrected to a BMI of 27.5
kg/m2
Health Council of the Netherlands (carbohydrate 40 energy% and fat 20-40 energy%). 
For the micronutrients and product groups, the Dutch Recommended Daily Allowance
(DRDA) was used as reference. Finally, the intake of nutrients and product groups was
compared to the Dutch national Food survey (DnFs) [13]. Because references differed 
with age and sex, absolute numbers were converted into percentages of the reference 
values in which 100% equals the recommendation. For fat the upper limit of the healthy 
range, i.e. 40 energy%, was set equal to 100%.
Descriptive statistics were used to present the nutrient intake. Data were checked for 
normality and means were presented with their standard deviation or medians with their 
respective range. In case of normal distribution, one sample T-test was used to calculate 
reference data. Correction for multiple testing was performed using the Bonferroni 





Eighty nutrition diaries were collected from the Dutch adult MD patients population of
the RCMM. Twenty reports were excluded, see Figure 1. The study population available
for data analysis consisted of 60 nutrition diaries of 60 MD patients.
Figure 1. Patient report exclusion schedule.
Patients characteristics
Table 1 shows the characteristics of the MD study population. Nutrition diaries of
nineteen males (32%) and 41 women (68%), with a mean age of 49.2 years (± 13.1) and
a mean BMI of 24.3 kg/m2 (±4.6) were included in the study. The most frequent MD 
phenotypes were Mitochondrial Myopathy (MM, 35%), Maternally Inherited Diabetes
and Deafness (MIDD, 30%) and Chronic Progressive External Ophthalmoplegia (CPEO, 
30%). Thirty-tree percent of patients suffered from diabetes of which 80% were insulin 
dependent.
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Figure 2 shows the mean intake of micro- and macronutrients in relation to reference 
values with corresponding standard deviations, compared to the average intake of the
Dutch national Food survey (DnFs).The mean macro- and micronutrient intake of the MD
patients was different from reference values (p<0.0025) with the exception of fat and iron. 
data, the intakes of carbohydrate, protein, saturated fat, and vitamin B12 were higher 
than recommendations. Variation in nutritional intake was high, especially in vitamin B12.
Figure 2. Intake of macro- and micronutrients in MD patients and DnFs expressed as percentage 
from DRDA. (Mean ± SD)
Protein intake was higher than the Dutch Recommended Daily Allowance of 0.8 g/kg.
The mean protein intake in the MD patients was 1.1 g/kg (SD ± 0.34).
Product groups
3). The intake of food for each product groups was below the DRDA, while the intake of 
meat was higher than the DRDA.
compared with the DnFs. Furthermore, although below DRDA reference, the intake
45
Patients with mitochondrial disease have an inadequate nutritional intake
3
compared to the Dutch national Food survey.
Figure 3. Food group intake in MD patients and DnFs expressed as percentage from DRDA 
(Mean ± SD)
Correlation dairy products with protein and calcium
A correlation of 0.74 (p<0.001) was observed between the consumption of calcium and 
dairy products. Furthermore, a correlation of 0.4 (p= 0.002) was observed between the 
consumption of protein and dairy products.
Snacks, soft drinks, and mono- and disaccharides
the average Dutch intake. The mean intake of soft drinks was higher in the patients while
recommendations according to DRDA. When categorizing the MD patients in diabetic
or non-diabetic patients this lower intake of mono- and disaccharides was only found in
the diabetic group (n=20) (Table 2).
Table 2. Mean intake of snacks, soft drinks, and mono- and disaccharides in MD patients.
Mean MD patients (±SD) Mean DNFCS
Snacks (g) 72 (±56.5) 63
Softdrinks (ml)* 249 (±421.5) 86
Mono- and disaccharides (g)* 86.5 (±42.6) 102
Non-diabetic patients 93.5 (±47.1)
Diabetic patients * 72.6 (±28.1)




Information on nutritional supplement use of 44 patients was obtained. Of these, 
68 percent consumed one or more nutritional supplements. Coenzyme Q10 was mostly 
used (44%) followed by multivitamin supplements (32%). One patient used enteral nutrition.
DISCUSSION
The aim of this study was to describe which nutrients and/or product groups are
that the nutritional intake of adult MD patients is inadequate according to the DRDA 
and the individual variation in intake is high. However, this also applies to the healthy
malnutrition, leading to secondary mitochondrial dysfunction, resulting in worsening of 
symptoms [6].
to the healthy Dutch population, but still well above the recommendations for healthy 
individuals. As MD patients are not healthy, protein requirement may be different in 
these individuals. For instance, in some patients with renal involvement the protein intake
should be restricted [18]. On the other hand, malnutrition is frequently found, leading to 
increased protein needs. Protein recommendations in malnutrition are minimal 1.2 g/kg 
[19] which is higher than the mean intake of the MD patients. This lower protein intake 
MD patients: a moderate correlation between protein and dairy products was calculated. 
Avoidance of dairy products may be explained by frequent gastro-intestinal problems,
especially related to bloating and abdominal cramps [2]. Adequate intake of dairy products 
is important in MD patients not only because of protein, but also because of calcium 
intake was too low in MD patients, increasing the risk for osteoporosis [20]. MD patients 
already have a higher risk for osteoporosis because of low physical activity and persistent
lactic acidosis [21]. In addition, vitamin D intake was, although not different between MD
patients and DnFs, extremely low. An adequate vitamin D status is particularly important 
weakness [22] which is a key complaint in these patients [1]. Taken together the inadequate 
intake of protein and dairy products is a serious concern in the diet of MD patients.
gastrointestinal distress in these patients [2] caution should be paid to these nutrients.
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known that the energy demands of MD patients are usually below recommendations
for healthy individuals because of the lower physical activity [16]. Because it is assumed
that their nutritional requirements are not different [9] from normal individuals, the 
nutrient density of the diet should therefore be higher than in patients with normal 
patients. Data from our study did not support our hypothesis that MD patients eat more 
unhealthy than the general population. Although they did consume high levels of sugar,
snacks, and saturated fat, this was not different from the consumption of the general
Dutch population. Nevertheless, healthy eating is particularly important for MD patients, 
because of the increased risk for diabetes, fatigue, and metabolic syndrome [1, 23]. The
high saturated fat intake is relevant, as cholesterol-lowering statins is discouraged in MD
patients because of the risk of statin myopathy [24].
Previous research regarding supplement use in MD patients in a partly overlapping 
cohort (n=33) revealed that 70% of patients used nutritional supplements [25]. These
products were coenzyme Q10 and multivitamin supplements. The supplement use is
protein supplements were barely used. Given the increased incidence of malnutrition in 
MD patients [2] prescribing enteral nutrition or mineral and vitamin supplements tailored 
A strong point of this study is the relative large group of subjects with this rare disorder. 
Although the patient population was heterogeneous, this study provides unique insight 
in the food intake of MD patients in general.
A weakness of the study is that the use of nutrition diaries may lead to bias in the results. 
Interpretation errors, as well as underreporting or overreporting, are possible reasons 
for this [26]. However, in a retrospective study it is not possible to change the method of 
data collection, and nutrition diaries provide valuable information that qualitatively seems
better than the frequently used dietary history [27]. Furthermore, the data collection 
method used in the DnFs is the 24-hour dietary recall of any two nonconsecutive days. 
This method is different from the method used in our study. These weaknesses should 
be taken into account when interpreting the study results.
Overall, it may be concluded that patients with MD have an inadequate diet. Calcium, 
saturated fat, and vitamin D intake differ from general recommendations. Using a healthy 
and adequate diet is especially important in MD patients, because of the increased risk 
of gastrointestinal problems, diabetes, metabolic syndrome, muscle weakness, fatigue,
and osteoporosis. Because individual differences are considerable, a patient-tailored 
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approach is recommended in which all adult MD patients are provided with individual
diet counseling for obtaining a healthy adequate diet.
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Whether decreased physical functioning of patients with mitochondrial disease (MD) 
background of the nutritional state.
Methods
In this 2-site cross-sectional study, MD patients were age-, BMI- and gender-matched to 
controls. Body composition was assessed by dual-energy x-ray absorptiometry. Physical
functioning was measured by handgrip strength, 6-minute walking test (6MWT), 30-
second sit-to-stand test (30SCT), and 6-minute mastication test (6MMT). Total daily 
protein intake was calculated by three-day food records. Malnutrition was assessed by
Patient-Generated Subjective Global Assessment and the Global Leadership Initiative on 
Malnutrition (GLIM) criteria, and sarcopenia by the 2018 consensus. Data were analyzed
using independent samples t-
Results
Thirty-seven MD patients (42±12 years, BMI: 23±4 kg/m2, 59% female) and 37 matched
controls were included. Handgrip strength was moderate inversely related to fat mass 
index in both MD patients and controls, whereas it correlated with fat free mass index 
in controls solely. Protein intake was associated with muscle strength (handgrip strength 
and 30SCT) in MD patients but not in controls. Twenty-seven MD patients (73%) were
Conclusions
Muscle strength is related to body composition and protein intake in MD patients. This
in combination with the high incidence of both malnutrition and sarcopenia warrants 
individual nutritional assessment in MD patients.
Clinical Relevancy Statement
Physical functioning is chronically impaired in adult MD patients implicating decreased
quality of life. Insights in the relation between protein intake, body composition and 
physical functioning in these patients and the prevalence of malnutrition and sarcopenia





Approximately one out of 5000 persons worldwide is confronted with mitochondrial 
disease (MD) [1], a genetic neuromuscular chronic disorder causing intracellular energy
(ATP) shortage [1]. As MD patients experience a wide range of complaints, such as fatigue, 
muscular weakness, gastrointestinal complaints, dysphagia and exercise intolerance [2, 3] 
treatment focuses on symptom relief, securing physical functioning and quality of life [2].
Poor physical functioning is predicted by a body weight that is either too low or too
high [4-7], conditions that are frequently observed in MD patients [8-12]. Also, body
composition is known to be an important factor in physical functioning in the general
population as well as in neuromuscular disorders in particular [6, 7, 13, 14]. Decreased
physical functioning was related to an increased fat mass in patients with myotonic 
dystrophy [13] or with decreased muscle mass in patients with muscular dystrophy [7, 
15, 16]. In patients with chronic symptoms similar to mitochondrial disease, like kidney 
disease [17], lower fat free mass and decreased muscle strength were associated. An 
increased muscle mass and strength may also be related to lower diabetes risk [18]. 
Altered body composition in MD patients has been reported [9, 12] and higher skeletal
muscle mass index in these patients was correlated with higher muscle strength [12]. 
However, whether physical functioning is related to fat mass has not been established
yet.
It is known that physical activity improves physical function and body composition 
[19]. The decreased physical activity in MD patients [10] is likely to play a role in body 
composition and physical functioning in these patients. However, it is not known whether
patients can be improved by physical exercise [20] therefore exercise is part of standard 
care in MD patients [21].
The combination of low muscle mass and low muscle strength seen in MD patients may
as survival [22, 24]. Therefore, it is relevant to know whether sarcopenia is present in 
MD patients, in order to adjust treatment accordingly [25].
The low physical functioning in MD patients may also be related to alterations in
nutritional intake and the nutritional status. Recent observational studies suggested 
that MD patients have inadequate protein intake and are at risk of malnutrition [9,
25-27]. This could affect both body composition and physical functioning. Diagnosing 
malnutrition in MD patients is challenging [9, 28]. Standard screening tools aimed at 
screening acute malnutrition are not applicable in MD patients as these patients 
suffer from chronic malnutrition [25]. Recent literature advises to perform nutritional 
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assessment for determine nutritional state in MD patients [9, 25, 27], but it is not known
which measurements are valid nor which cutoff values should be applied.
The primary goal of this study is to explore the association between physical functioning,
protein intake and body composition in adult MD patients. Additionally, the prevalence of
malnutrition and sarcopenia in this MD population is assessed using various nutritional 
assessment tools. Finally, the diagnostic accuracy of BIA to determine body composition 
in MD patients was tested.
METHODS
In this two-site, cross-sectional study the associations between physical functioning, 
protein intake and body composition were examined in MD patients compared to age-,
body mass index (BMI)-, and gender-matched controls. The study protocol was approved 
by the ethics committee of the Nijmegen-Arnhem region (NL58262.091.16/2016-2667).
Primary and secondary endpoints
The primary endpoint was the association between physical functioning, protein intake 
and body composition in MD patients. The secondary endpoint is the prevalence of 
malnutrition and sarcopenia in MD patients.
Study population
included MD patients for age- (+/- 5 years), BMI- (+/- 2 kg/m2), and gender. Exclusion 
criteria were (1) a pacemaker or implant, (2) pregnancy or lactating, (3) disordered 
hydration status (edema, dehydration), (4) diagnosed with a (chronic) disease interfering 
with the nutritional assessment, or (5) acute illness and fever. Additionally, MD patients
none myopathic MD phenotype, or (3) if DXA and handgrip strength data were not 
available.
A sample size of 37 MD patients and 37 controls was calculated using data of MD patients 
(n=24) and compared with the reference values of Dodds [29] to show a difference of 
physical functioning between MD patients and controls with a power of 0.80 and an 
alpha of 0.05 based on an estimated dropout rate of 30% using the handgrip strength 
as primary outcome variable for physical functioning.
Data collection




January 2017. MD patients were measured during a four-day multidisciplinary evaluation 
program (as usual care) on the internal medicine ward. Controls were measured at the
Nutritional Assessment Lab of the HAN University of Applied Sciences between August 
2017 and July 2018.
Demographic and disease characteristics
Age (years) and gender were collected from electronic records in MD patients or obtained
well as the presence of dysphagia or gastrointestinal problems were registered.
Physical functioning
Physical functioning was assessed according to the applicable standard operating 
procedures using four tools relevant for MD patients. Muscle strength was measured
Anthropometry and body composition
Height (cm), weight (kg), and waist circumference (cm) were measured to the nearest 
one decimal point. Total fat mass (kg), total appendicular skeletal muscle mass (kg), and 
regional lean tissue mass (kg) were determined by whole-body DXA (Radboudumc:
200103) [34]. Fat mass, appendicular skeletal muscle mass, as well as regional lean tissue 
mass were normalized by dividing total mass (kg) by height (m) squared into fat mass
index (kg/m2), skeletal muscle index (kg/m2), and regional lean tissue mass index (kg/
m2), respectively.
Additionally, bioelectrical impedance analysis (BIA) measurements were performed 
according to clinical practice (Bodystat MDD 1500, 50 Hz). Fat free mass (kg) was 
calculated twice using 1) Kyle formula [35], having the smallest standard error and highest 
R squared [35] and 2) Dey being validated in elderly [36].
The diagnostic accuracy of the BIA was tested using the DXA as golden standard. The 
2 and <17
kg/m2 for fat free mass index in women and men respectively [37] and obesity as fat 
percentage >30% for women and >25% for men [38].
Nutritional intake
Nutritional intake was assessed by either a three-day food record or, in case missing in
clinic, a dietary history using the nutrition calculation program Madows®. Mean energy 




Malnutrition was assessed by Patient-Generated Subjective Global Assessment (PG-
The cutoff point for 70-year-old [22] people as well as the actual age cutoff point for low 
handgrip strength [29] were applied, as the majority of MD patients is younger than 70
year. Sarcopenic obesity was diagnosed according to Baumgartner [40].
Data management
Data were entered encoded in an online case report form (Castor ©, CIWIT B.V., 
Amsterdam) and double-checked visually by two researchers.
Statistical analysis
Data were reported as means ± standard deviation (SD), median and interquartile range,
or frequencies and percentage of the group or total population, if applicable. Normal 
distribution of the variables was assessed by Shapiro-Wilk tests. Differences between 
MD patients and controls were tested using the independent t-test or Mann-Whitney 
categorical variables.
between physical functioning, (regional) body composition and protein intake. Since fat
free mass index and skeletal muscle mass index were associated, only fat free mass index 
was used in association analysis. Statistical analyses were performed using SPSS statistics 
RESULTS
Thirty-seven MD patients and 37 matched controls (all Caucasian) were included in
this study (Figure 1). Mean age was 42±12 years and 59% was female (Table 1). Despite 
having similar BMI, MD patients had a shorter statue compared with controls. Compared
with controls, MD patients were on a (diabetes) diet, experienced gastrointestinal 
problems or dysphagia more often. The majority of the MD patients were diagnosed 




Figure 1. Screening-Flowchart of MD patients and controls in the DYNAMO study.
Table 1. Demographics of MD patients and controls.
MD patients (n=37) controls
 (n=37)
p-value
Age (years, mean ± SD) 42 ± 13 42 ± 12 0.84
Female (n/%) 22 (59%) 22 (59%)
BMI (kg/m2, median: IQR) 21.9: 19.9 – 24.5 23.0: 21.3 – 25.0 0.54
BMI categories (n/%):
< 18. kg/m2 2 (5%) 0 (0%)
< 20 kg/m2 9 (24%) 4 (11%)
20-25 kg/m2 20 (54%) 23 (62%)
25-30 kg/m2 6 (16%) 10 (27%)
>30 kg/m2 2 (5%) 0 (0%)
Weight (kg, mean ±SD) 66.6 ± 12.3 72.2 ± 8.9 0.04
Weight loss1 (n/%) 4 (11%) 2 (5%) 0.39
Height (cm, mean ±SD) 170.8 ± 1.0 176.4 ± 0.9 0.01
Waist circumference (cm mean ± SD) 84.3 ± 11.5 81.8 ± 8.0 0.30
High Waist circumference 2 (n/%) 14 (38%) 12 (32%) 0.46
Diet (n/%) 25 (68%) 2 (5%) <0.001
Gastrointestinal problems (n/%) 28 (76%) 5 (13.5%) <0.001
Dysphagia (n/%) 18 (49%) 0 (0%) <0.001
in bold
1) Weight Loss according to GLIM criteria: >5% within past 6 months, or >10% beyond 6 months [30]
2) High waist circumference >94 cm (women) and >80cm (men) according to WHO 2008 [44].
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Table 2. Disease Characteristics of Mitochondrial Disease Patients (n =37).
Frequency (n) Proportion (%)
Genotype
m.3243A>G 29 78
point mutations (mtDNA) 5 14
nDNA mutation 2 5
deletion mtDNA 1 3
Phenotype




Leigh syndrome 2 5
MERRF 1 3
CPEO, Chronic progressive external ophthalmoplegia; mtDNA, mitochondrial DNA; MELAS,
Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF, Myoclonus epilepsy 
Physical functioning
Physical functioning in MD patients was lower compared to controls based on all physical 
functioning tests (Table 3).
Body composition
Total appendicular skeletal muscle mass was lower in MD patients compared with 
controls (p<0.02) (Table 3), whereas no differences in total body fat or muscle mass 
were observed. Also, leg lean tissue mass index was lower in MD patients compared to 
controls (Table 3).
Association between physical functioning and body composition
Handgrip strength was increased with higher fat free mass index in controls (Pearson 
r = 0.67, p < 0.001), but not in MD patients (Pearson r = 0.30, p = 0.08) (Figure 2a). In
m.3243A>G mutation genotype subgroup (Spearman r = 0.31 p = 0.06 and r = 0.44, p 
< 0.02 respectively) was observed (Supplement 1). Handgrip strength declined in both
MD patients and controls with higher fat mass index (Spearman r = -0.61 and r = -0.49, 
p < 0.01) (Figure 2b).
Nutritional intake




Figure 2. Association between handgrip strength, 30-second sit-to-stand test, fat mass index, fat 
free mass index and protein intake. HGS, Handgrip strength, FMI, fat mass index, FFMI, fat free mass 
index, 30SCT, 30-second sit-to-stand test. P-values <0.02 (in bold)
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Table 3. Physical functioning, body composition, nutritional intake, malnutrition and sarcopenia 
in MD patients and controls.




Handgrip strength (kg) (mean ± SD) 28 ± 10 43 ± 9 < 0.001
Too low handgrip strength 1 (n/%) 6 (16) 0 (0)
Too low handgrip strength 2 (n/%) 15 (41) 0 (0)
6-MMT (n chewing cycles) (M ± SD) 396 ± 130 (n=29) 577 ± 141 (n=36) < 0.001
30SCT (n sit-to-stands) (mean ± SD) 12 ± 4 (n=22) 17 ± 4 (n=36) < 0.001
6-MWT (distance in m) 441: 426-427 (n=20) 681: 635-639 < 0.001
6-MWT < 400 m (n/%) 3 (15) 0 (0)
Total body composition
FMI (kg/m2 7.7 :6.7-8.7 7.0 :6.3-7.7 0.25
Fat percentage (%) (mean ± SD) 22 ± 7 16 ± 7 0.21
high fat percentage3 (n/%) 9 (24) 7 (19) 0.21
ASM (kg) (mean ± SD) 17.6 ± 4.0 19.8 ± 3.8 0.02
FFMI (kg/m2) (mean ± SD) 15.2 ± 1.9 15.5 ± 1.6 0.38
SMI (kg/m2) (M ± SD) 6.0 ± 1.0 6.3 ± 0.9 0.11
Too low SMI4 (n/%) 25 (68) 21 (57) 0.34
Bone density (g/cm2, mean ± SD) 0.31 ± 0.83 0.27 ± 0.80 0.99
Osteopenia5 (n/%) 3 (8) 0 (0) 0.08
Regional LTMI (kg/m2, mean ± SD)
Average arm 1.3 ± 0.30 1.3 ± 0.3 0.42
Trunk 12.7 ± 2.0 13.1 ± 1.5 0.34
Average leg 3.8 ± 0.7 4.3 ± 0.6 0.004
Nutritional Intake
Protein intake (g/kg/day) 1.1: 0.9-1.4 1.2: 1.1-1.7 0.07
Too low protein intake6 (n/%) 25 (68%) 4 (12%) < 0.01
Energy (kcal/d) 1663 ± 500 2322 ± 644 < 0.001
Kcal intake (% of calculated needs, mean 
± SD)
81% ± 238 98% ± 251 0.03
Too low Kcal intake7 (n/%) 25 (68%) 17 (46%)
PG-SGA8 < 0.001
PG-SGA8 0-4 (n/%) 5 (14%) 35 (95%)
PG-SGA8 4-9 (n/%) 16 (43%) 1 (3%)
PG-SGA8 16 (43%) 1 (3%)
Malnutrition9 (n/%) 17 (46%) 10 (27%) 0.09
Severe Malnutrition9 (n/%) 1 (3%) 0 (0%)
Sarcopenia10 (n/%) 5 (14%) 0 (0%) 0.02




SD, standard deviation; IQR, interquartile range; 30SCT, 30-second sit-to-stand test; 6MWT, 6-minute
walk test; 6MMT,6-minute mastication test; ASM, Appendicular muscle mass; FMI, fat mass index; FFMI,
in bold) were 
Dodds reference at age 70 [29] according to the sarcopenia consensus 2018 [22]. 2) too low handgrip 
strength based on de Dodds reference [29] according to actual age.3) high fat percentage according to 
the sarcopenic obesity criteria of Baumgartner = >28% for men and >40% for women [40]. 4) too low 
SMI <7.0 kg/m2 for men and <6.0 kg/m2 for women according to the recommendations from European
Working Group on Sarcopenia in Older People 2 (EWGSOP2) [22, 30].5) Ostopenia = t score between
-1 and -2,5.6) too low protein intake = <1,2 gram/kg/day for MD patients at risk for malnutrition = PG-
day for controls and MD patients not at risk for malnutrition. 7) to low Kcal intake <90% of calculated
energy needs = resting energy expendure according to the Harris and Benedict formula (1984) and an 
activity factor of 1.4 for mobile MD patients, 1.2 for immobile MD patients and 1.5 for controls [10]. 8)
PG-SGA, Patient-generated subjective global assessment: 0-1 does not require nutritional intervention,
need of symptom management together with specialized nutritional intervention/malnutrition [39].9) 
Malnutrition and severe malnutrition according to GLIM criteria [30].10) Sarcopenia according to 2018 
consensus [22]. 11) Sarcopenic obesity according to Baumgartner [40] low SMI and high fat percentage.
Association between physical functioning and protein intake
Protein intake was inversely correlated with fat mass index in MD patients (Spearman 
r = - 0.55, p < 0.01) and controls (Spearman r = -0.39, p = 0.02) (Figure 2c). Physical 
function was increased with higher protein intake in MD patients as measured by the 
30SCT (r = 0.57, p = 0.006) (Figure 2d) and handgrip strength (Spearman r = 0.39, 
p = 0.02) (Supplement 2), but not in controls.
Other associations
Protein intake and handgrip strength correlated with arm lean tissue mass index in MD 
patients and controls, respectively (MD patients: Pearson r = 0.53, p <0.01 and controls:
Pearson r = 0.81, p <0.001). No correlations were found between either the 6MWT, nor
the 6MMT and body composition in MD patients and controls. The 30SCT correlated
with fat mass index (r = 0.41, p = 0.01), but not with fat free mass index (r = 0.01, p = 0.96) 
in controls solely. No correlations were found between the 30SCT and 6MWT with leg
lean tissue mass index. 6MMT correlated moderately with protein intake (Spearman 
r = 0.45, p = 0.02) in MD patients (Supplement 2).
Malnutrition and sarcopenia
According to the PG-SGA, 32 MD patients (86%) needed a nutritional intervention, 
whereas, this was only the case in two controls (6%) (Table 3). According to the GLIM 
criteria 46% of the MD patients were malnourished, whereas 43% according to the 
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PG-SGA (Table 3). If the PG-SGA date were combined with the GLIM data 27 MD 
of the MD patients using either the consensus criterion or the actual age cutoff point 
for low handgrip strength, respectively.
Diagnostic accuracy of BIA versus the DXA
Both BIA-derived fat free mass formulas of Kyle and Dey show good correlation with 
DXA fat free mass in MD patients (Kyle r2 = 0.9, Dey r2 = 0.8) as well as in controls
(Kyle r2 = 0.94). BIA tends to overestimate fat free mass compared to DXA (mean 
difference = 1.8 kg, p :
(57%) to diagnose obesity are lower than to diagnose malnutrition (sensitivity 77%, 
DISCUSSION
and protein intake in MD patients.
Hou et. al. (2019) [12] found a positive correlation between skeletal muscle mass 
index and muscle strength (r = 0.4) which is consistent with our hypothesis but was 
association between skeletal mass index and handgrip strength was found in the
m.3243A>G genotype subgroup (supplement 1) and a moderate association between
handgrip strength and arm lean tissue mass index was found.
Surprisingly sarcopenia existed in MD patients only, while no difference in muscle 
mass between MD patients and controls was observed. This might imply that handgrip
strength and body composition are differently associated in MD patients compared with
strength between controls (Pearson r = 0.67, p < 0.001), and MD patients (Pearson 
r = 0.30, p = 0.08, Figure 2a).
the GLIM criteria 46% of the MD patients were malnourished, whereas 43% according 
to the PG-SGA (Table 3). This seems a consistent result, however, Figure 3 shows low
comparability in malnutrition between the two methods. A better comparability was 
seen between sarcopenia and malnutrition since all patients diagnosed with sarcopenia 
challenges of diagnosing malnutrition and the conclusions of Aubry et al. (2017) [9]
that nutritional assessment should be part of patient care in all adult MD patients. For




of the higher accuracy. For physical functioning it is advisable to measure handgrip 
strength and use the actual age cutoff point of the Dodds reference [29]. The incidence
of sarcopenia with this actual age cutoff point (27%) is very similar to the results of 
Hou et al. (2019) [12] who observed sarcopenia in 24.7% of the MD patients. The risk
for malnutrition according to the PG-SGA is higher in the current study compared to 
the slightly overlapping cohort from the DINAMITE study [27] 89% versus 55%. The 
DINAMITE study-cohort consisted of outpatients whereas the DYNAMO study-cohort 
et. al. [12] body composition is a sensitive biomarker of disease severity in MD patients. 
As low muscle mass is an indicator for malnutrition the difference in malnutrition risk
observed in the two studies is probably due to differences in disease severity.
Figure 3. -
copenia consensus 2018.
Except for lower statue, lower appendicular skeletal muscle mass and lower leg lean 
tissue mass index, body composition in MD patients was not different compared to
higher fat mass and lower lean mass in MD patients, which is similar to other studies [9,
12]. In the study of Aubry et al. (2017) [9], MD patients had higher BMI with comparable
weight than MD patients in the current study. Moreover, that MD-patient group
consisted of more males and had a higher mean age compared to the current study [9].
As height and body composition are known to be gender- and age-related [7, 13] this may 
have contributed to the (larger) difference in body composition observed in the study 
body composition in the current study with reference values [41], a low skeletal muscle
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index in both MD patients and controls (68% versus 57%) was observed. This result was
anticipated for the MD patients, but not for the controls, and might indicate that either
the controls do not represent a healthy status of body composition or the reference data 
are not representative for the healthy Dutch population.
controls (p = 0.07). However, relative to their protein needs, more MD patients have a 
protein intake that is too low (68%) compared to controls (12%).
The matched-control design, together with the accurate measurement of whole and
regional body composition using DXA are strengths of this study. The small study sample 
size is a shortcoming. However, taking into account the low prevalence of MD, a total of 
37 MD patients is considerable.
Data collection bias may have occurred due to having multiple professionals performing
the measurements, although standard operating procedures have been applied. Validity 
the body composition was not different in MD patients compared to controls could not
was no difference between body composition in MD patients compared to controls 
(supplement 3). Furthermore, underreporting or overreporting of nutritional intake 
might have occurred.
Causal relationships could not be established in this study. The associations observed
is known to be dependent by physical strength exercise and also gender and age play a 
big role [42]. Gender and age cannot be changed but exercise and nutrition intake are
Although fat mass did not differ between MD patients and controls, MD patients
frequently have a high fat percentage (24%, Table 3) and high waist circumference (38%,
Table 1). As patients with neuromuscular disease are at risk for developing metabolic 
syndrome [43], monitoring body composition is recommended. If DXA is not available and
waist circumference in MD patients is the preferred method. Nutritional strategies 
aiming at improving physical functionality and preventing metabolic syndrome are 
recommended. Improving protein intake seems a good start because a positive moderate
association between protein and muscle strength was found as well as a moderate
negative association between fat mass and protein intake. Prospective intervention 






In conclusion, MD patients have decreased physical functioning. There is a moderate 
inverse association between handgrip strength and fat mass index in MD patients and
controls, between handgrip strength and fat free mass index only in controls and between 
protein intake and muscle strengths in MD patients only. This, in combination with the
high prevalence of both malnutrition and sarcopenia, warrants nutritional assessment in
MD patients. Future intervention studies on improving protein intake are recommended.
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Correlations between HGS and body composition (FFMI, SMI and FMI) in different genotypes 
of mitochondrial diseases.













Others (n=5 point mutations (mtDNA), n=2 nDNA 

























FFMI, fat free mass index (kg/m2); FMI, fat mass index (kg/m2); HGS, handgrip strength (kg); r, Spearman 
correlation P-values < 0.02 (in bold
We tested the correlation between handgrip strength and body composition for 
genotype and categorized it into groups with a minimal of 8 patients and used spearman
























































































































































































































































































































































































































































































































































































































































































Diagnostic accuracy of BIA versus DXA in adult mitochondrial disease patients
36 MD patients (age 42 ± 12 years, 40% males) +37 matched controls
Table 1. Difference FFMI and FMI between BIA and DXA.
FFMI M±SD (kg/m2) FMI Median IQR (kg/m2)
MD patients controls P value MD patients controls P value
DXA 15.2± 1.9 15.5 ± 1.6 0.38 7.7 :6.7-8.7 7.0 :6.3-7.7 0.25
BIA 15.9 ± 1.7 16.7 ±1.6 0.04 6.9:5.9-8.0 6.3:5.8-7.2 0.53
P value <0.001 <0.001 <0.001 <0.001
BIA, Bioelectrical impedance analysis DXA, Dual-energy X-ray absorptiometry, M, mean; SD, standard
deviation; IQR, interquartile range, FFMI, fat free mass index (kg/m2); FMI, fat mass index (kg/m2);P-values 
<0.02 (in bold
Table 2. Correlation FFM BIA formula Kyle and Dey versus DXA.
FFM R2 SEE (kg) P value Data source
Kyle healthy from literature [1] n=343 0.97* 1.8 <0.0001 Kyle et al (2001) [2] BIA = Xitron
Kyle controls n=37 0.94 1.9 <0.0001 Dynamo study
Kyle MD patients n=36 0.90* 2.6 <0.0001 Dynamo studya
Dey MD patients n=36 0.89* 2.4 <0.0001 Dynamo study
BIA, Bioelectrical impedance analysis DXA, Dual-energy X-ray absorptiometry, FFM, fat free mass (kg);
P-values <0.02 (in bold
Blant altman plot
Figure 1. Blant altman plot FFM DXA versus BIA by Kyle in MD patients. BIA, Bioelectrical imped-






BIA Yes 17 (77%) * 1 (7%) 18
No 5 (23%) 13 (93%) ** 18
Total 22 14
FFMI, fat free mass index (kg/m2 2 for women and < 17 kg/




BIA Yes 19 (66%) * 3 (7%) 22
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We aimed to identify the optimal method to estimate total energy expenditure (TEE) in 
mitochondrial disease (MD) patients.
Methods
Resting energy expenditure (REE) was measured in MD patients carrying the m3243A>G
mutation using indirect calorimetry (IC) and compared with results of 21 predictive 
equations (PEs) for REE and with REE-IC measurements in healthy controls. Physical
activity level (PAL) was measured using accelerometry (Sensewear®) and compared 
calculated as REE-IC × PAL Sensewear® and compared with usual care and energy
recommendations for healthy adults.
Results
2
and 25 matched controls were included. The accuracy of most PEs was between 63% 
and 76%. The difference in REE-IC in healthy controls (1532±182 Kcal) and MD patients
P
accurate. Patients overestimated their PAL. Usual care predicted TEE accurately in only
32% of patients.
Conclusion
TEE is lower in these MD patients than the recommendations for healthy adults because 
of their lower physical activity. In MD patients, 6 PEs for REE provide a reliable alternative 
for IC, with an accuracy of 71%-76%. As PAL is highly variable and not reliably estimated
by patients, measurement of PAL using accelerometry is recommended in this population.
Clinical Relevancy Statement
This study provides innovative information on total energy expenditure which can
help guide individual dietary treatment of patients with mitochondrial disease. Energy 
requirements are very relevant for this patient population since the energy production 
in these patients is decreased.
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INTRODUCTION
Mitochondria are responsible for the transformation of energy from nutrients 
into adenosine triphosphate (ATP), through oxidative phosphorylation (OXPHOS).
Mitochondrial dysfunction can result from mutations in either nuclear DNA (nDNA) 
or mitochondrial DNA (mtDNA). The incidence of primary mitochondrial disorders is
approximately 1:5000 of all live births [1]. The most frequently reported pathogenic 
mitochondrial mutation in adults is the m.3243A>G point mutation [1, 2]. The most
frequently reported phenotype of the m.3243A>G mutation is Maternal Inherited 
Diabetes and Deafness (MIDD) but also Mitochondrial Myopathy is very common. 
Mitochondrial Encephalomyopathy and Lactate Acidosis and Stoke-like episodes 
(MELAS) is a more severe phenotype with a lower incidence. Frequently occurring
symptoms are hearing loss, gastro-intestinal symptoms, exercise intolerance, diabetes 
Accurate prediction of total energy expenditure (TEE) is crucial to guide individual dietary
treatment [4] since MD patients are both at risk for malnutrition [5-7] and overnutrition
with a higher risk for comorbidities and metabolic syndrome [4, 8, 9].
At this point, it is not clear if and how the mitochondrial disease affects energy
requirements. Defects in the oxidative phosphorylation system (OXPHOS) could 
theoretically lead to a lowered oxygen consumption rate at the cellular level [10] with
lower REE. A lower fat free mass such as is frequently seen in MD [4-7] might also lower 
when assessing Indirect Calorimetry in 20 children with MD [12]. On the other hand, 
the lactic acidosis that frequently occurs in mitochondrial disease may induce increases
in the volume of CO2 production based on exhaled CO2 (VCO2). This could mean a 
MD as compared to healthy controls.
Mitochondrial Diseases are a heterogeneous patient group in whom nutritional intake 
tends to be inadequate [13]. Measuring REE using indirect calorimetry is recommended 
[5, 12], but this is a relatively expensive method that requires the presence of trained
personnel. For this reason, REE is often estimated in an indirect manner by means 
of predictive equations [14]. It is known that these predictive equations are not very 
accurate at individual level [14] but how accurate they are in mitochondrial disease is 
not known.
that patients with MD are less active than healthy controls in this respect [8, 16]. Physical 
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activity can be reliably measured using non-invasive accelerometery [17]. This, however, 
is not implemented in most clinical settings and in usual care PAL is mostly estimated 
based on anamnestic data obtained from patients or by the use of standard PAL based
on literature [8] or protocols [11, 18].
The aim of this study was to identify the optimal method to estimate total energy 
expenditure in MD patients. Also, we wanted to learn whether the energy requirements 
in adult MD patients differ from healthy adults.
MATERIALS AND METHODS
Standard protocol approvals, registrations and patient consents
This study was conducted in accordance with good clinical practice and the Declaration 
of Helsinki. The Medical Ethics Committee of the Arnhem and Nijmegen region approved
the study protocol (NL 39724.091.13/2013/146) and written informed consent was
obtained from every patient.
Study design/patients
In this study we used baseline data of the DINAMITE study, a randomized controlled trial
with an individual dietary intervention in adult patients with MD due to the m.3243A>G 
mutation [4], as well as healthy control data from the DYNAMO study, a cross-sectional
study on the association of body composition, physical functioning and protein intake in 
adult patients with mitochondrial diseases [7].
Thirty-nine patients with MD due to the m.3243A>G mutation from the Radboudumc 
patient cohort were included in the DINAMITE study. These could participate when they
were at least 18 years of age, had no medical contraindication to undergo Nutritional 
Assessment after overnight fast, had no cardiac pacemaker nor did they suffer from 
claustrophobia. Patient measurements were performed between 2014 and 2017.
Maternal lactation was another exclusion criterium for this study. Seventy-three healthy
controls were included in the DYNAMO study: we used only the data of controls that on
average matched for gender, age (± 2 years) and BMI (± 1 kg/m2).
Phenotype, the Newcastle Mitochondrial Disease Adult Scale (NMDAS) [19] and 
heteroplasmy levels of the mutation measured in urinary epithelial cells (UEC) [20] were
Anthropometrics
Height (cm) and weight (kg) were measured. The Fat Free Mass (FFM) was estimated
by single frequency bioimpedance analysis (BIA) (Bodystat 1500 MDD) at 50 Hz, FFM
(kg) was calculated according to the formula presented by Kyle [21].
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Resting energy expenditure
As gold standard for Resting Energy Expenditure (REE) (Kcal) Indirect Calorimetry 
(IC) was measured as assessed for 20-30 minutes with the Cosmed Quark RMR®
lying down with the canopy after an overnight fast according to the Dutch national 
Standard Operating Procedure. The REE-IC was compared to the results of 21 predictive 
equations, including 4 that incorporate FFM (See Supplement 1), and to the REE-IC of 
healthy controls.
Physical activity level
Physical activity was measured using a validated multi-sensor actometer [22-25] 
(Sensewear®, Bodymedia with Sensewear pro algorithm version 5.2), which was worn 
over a 7-day period. Patients worn the device day and night they only must take it off
for showering.
Physical activity data are presented as average METS/day, where 1 MET = resting 
resting energy expenditure. Therefore, average METS were interpreted as PAL and used 
as gold standard.
The gold standard was compared to:
1. Patients estimated activity level scored by the Dutch activity Table (see Table 1)
a. Apabhai et al (2011) found in 100 genetically proved adult MD patients
with Sensewear® accelerometery an average PAL of 1.4 [8]: this result is
consistent with the average PAL in the DINAMITE study [4].
b. Literature on PAL in patients with various diseases advise to consider a 
PAL of 1.3-1.5. This value is therefore commonly used in dietary practice,
including in our centre [18].
3. Average PAL in healthy Dutch adults is considered to be 1.7 in persons up to 
50 years of age and 1.6 from 50 years and older [26]. The recommended PAL is 
higher: 1.9-1.8 [26].
Total energy expenditure
We compared our gold standard for total energy expenditure (= REE IC x PAL 
Sensewear®) to usual care and energy recommendations for healthy adults. The usual
care at our centre is to use the WHO formula with weight and height [14] as prediction
equation for REE for patients with a BMI <30 kg/m2 and Harris-Benedict (1918) [27] 
2 based on the study of Kruizinga et al (2016) [14]. This
care total energy expenditure. The energy recommendations are based on the WHO 
REE prediction equation + weight multiplied with a PAL of 1.7 < 50 year and 1.6 from 
50 years and older [26].
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Table 1. Activity level scored according to criteria from the Dutch Health Council 
(Gezondheidsraad) [26] translated into lower and upper PAL values as described by Black (1996) 
[15], based on double-labelled water measurements.
Activity level according to Black
(1996) [15]




Chair-bound or bed bound I use a wheelchair all the time. 1.2 1.2
Seated work with no option of moving 
around and little or no strenuous
leisure
I have limited activity, I alternate 
sitting with light housework and 
activities such as writing, washing
1.4 1.5
Seated work with discretion and 
requirement to move around but little
or no strenuous leisure activity
moderately active, I alternate
sitting with light and heavier
housework, gardening, walking, 
cycling, sports
1.6 1.7





Strenuous work or highly active leisure very active, I do heavy physical
work and/or I exercise a lot
2.0 2.4
PAL, physical activity level.
Statistics
Data were reported as means ± standard deviation (SD), or frequencies and percentage
of the group or total population, if applicable. Normal distribution of the variables was 
assessed by Shapiro-Wilk tests. Differences between MD patients and controls were 
tested using the independent t-test. Differences between estimated PAL and measured
PAL and between gold standard TEE with energy recommendations were tested using the
paired t-test. Accuracy of predictions for REE /PAL/TEE were evaluated as percentage
of subjects predicted within ±10% of measured REE/PAL/TEE, root mean squared error
(bias) and mean absolute percentage difference between predicted and measured REE/




because she was lactating. Twelve controls from the DYNAMO were excluded because
they did not match for gender, age and/or BMI.
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Resting energy expenditure
Table 3 shows statistics of the 21 REE predictive equations for the MD patients. The 
accuracy of most (n=15) predictive equations was between 63-76%. Three out of four 
predictive equations that use fat free mass (FFM) as a variable were below 50% accurate. 
The three best scoring REE formulas were Henry based on weight and height [28], Muller
using FFM [29] and Harris & Benedict (1984) [27]. The difference in REE-IC in healthy
controls (1532 ±182 Kcal) and MD patients (1430 ± 221) almost reached statistical 
Physical activity level
activity factor (1.4) was 53% accurate (see Table 4). Patients overestimated their physical
(p = 0.001 for the lower estimated PAL and p= <0.001 for the higher estimated PAL).
Total energy expenditure
Usual care accurately predicted TEE in only 32% of patients (see Table 5). Total 
recommendations (p<0.0001).
Figure 1. Resting Energy Expenditure measured by Indirect Calorimetry in Mitochondrial Disease 
patients and healthy controls. MD-Patients = Mitochondrial Disease Patients REE-IC = Resting 
Energy Expenditure measured by Indirect Calorimetry.
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Table 2. Patients characteristics.
Variable MD patients (n=38)
Age (years) 48 ±13
Female Gender 31 (82)
BMI (kg/m2) 24 (±4.2)
2) 2 (5)
Normal (BMI 18.5-25 kg/m2) 21 (55)
Overweight (BMI 25-30 kg/m2) 12 (32)
2) 3 (8)
NMDAS score 18 ± 10





METS Sensewear® = PAL 1.4 ± 0.25
FFMI (kg/m2) * 15.7 ± 2.3
Low n (%) 18 (47)
Normal n (%) 20 (53)
Self-estimated activity 
Limited active 11 (30)
Moderate active 17 (46)
Normally active 7 (19)
Very active 2 (5)
Wheelchair use
34 (92)
I only use a wheelchair outside with long distances 3 (8)
Activity stimulating factors
No activity stimulating factors 16 (43)
Rehabilitation program 3 (8)
Physiotherapy 8 (22)
Sports 12 (32)
BMI, body mass index; FFMI, fat-free mass index; MELAS, mitochondrial myopathy, encephalopathy, 
lactate acidosis, and stroke-like episodes; METS, metabolic equivalents; MIDD, maternally inherited 
diabetes and deafness; NMDAS, Newcastle Mitochondrial Disease Adult Scale; UEC, urinary epithelial
cells; Data shown as mean ± SD, number (%)* low or normal FFMI as compared to reference values by 
Pichard et al (2004) [31]
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DISCUSSION
energy expenditure in adult MD patients seems adequate in only 32% of all patients. 
While six available prediction equations for REE showed an accuracy of 71-76% and seem 
physical activity level proved not to be a suitable alternative to accelerometery.
The REE-IC in healthy controls seemed slightly (±100 Kcal) lower in MD patients as
compared to healthy controls (1430 ±221 Kcal in MD patients versus 1532 ±182 in
MD children versus controls [12]. Based on these limited data it seems fair to assume 
that REE of these MD patients does not substantially differ from healthy individuals and
does not have clinical implications.
The accuracy of 6 predictive equations was between 71%-76% (see Table 2). This is 
al [14] in a large hospital patient cohort (n=513). This suggests that for most MD patients
the use of one of these six prediction equations provides a relatively reliable alternative 
to indirect calorimetry. Yet, dietitians should be aware that predictive equations remain
estimations. The predictive equations can be used as an aid to the initial energy estimation, 
Patients estimations of physical activity level did not prove reliable alternatives for 
accelerometery, given their accuracy of only 18%-34%, with patients overestimating 
their physical activity level. It should be mentioned here that the activity table that we
used, and which has been validated for healthy individuals does not seem suitable for 
patients with exercise intolerance. For example, patients perform even light household 
tasks at a slower pace and with lower intensity. Because of our results, we recommend
using accelerometery in all adult MD patients as part of their nutritional assessment. 
This technique is not expensive and doable for patients, whereas the alternatives seem 
The total energy expenditure of MD patients is lower than that of recommendations for 
healthy individuals and since there was no difference in resting energy expenditure this 
with previous research in MD patients by Apabhai et al (2011) [8]. Since inter-individual 
differences in total energy expenditure may be substantial in this very heterogeneous 




The Sensewear® accelerometer has been reported to overestimate energy expenditure 
in healthy adults, especially at high intensities [25]. Although patients with a mitochondrial
disorder do not perform much intense activities [30] and the 5.2 version of the
Sensewear® pro algorithm that was used shows better validity for measuring energy 
expenditure than the older 2.2. version [24], this presents a methodological limitation.
Another shortcoming is the use of BIA to evaluate body composition. This is a double
indirect method and BIA is known to overestimate fat free mass compared with dual-
energy x-ray absorptiometry (DXA) in mitochondrial patients [7]. Finally, the use of the 
healthy energy recommendations as a control for total energy requirements instead of
using a healthy control group that had the same accelerometery + IC measurements is 
a limitation. The energy recommendations for healthy adults [26] are not very recent 
(2006) and based on local Dutch recommendations stemming from the international 
WHO recommendations which are even older (2001) [11].
CONCLUSION
Total energy expenditure in MD patients is lower than suggested by recommendations 
for healthy adults because of the lower physical activity of the former. In MD patients
six predictive equations for REE present a relatively reliable alternative for indirect 
calorimetry measurements. As PAL is highly variable and not reliably estimated by
patients themselves, measurement of PAL using accelerometery is recommended in 
reliable method than using patient estimated activity levels.
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SUPPLEMENT 1
Predictive equations resting energy expenditure.
Name formula Formula
Harris & Benedict 1918 [1] Men
Women
66,4730 + (13,7516 x weight (kg)) + (5,0033
x height (cm)) - (6,7550 x age)
655,0955 + (9,5634 x weight (kg)) + (1,8496
x height (cm)) - (4,6756 x age)
Harris & Benedict 1984 [1] Men
Women
88,362 + (13,397 x weight (kg)) + (4,799 x
height (cm)) - (5,677 x age)
447,593 + (9,247 x weight (kg)) + (3,098 x 
height (cm)) - (4,33 x age)
Weijs [2] BMI <25kg/m2
BMI >25kg/m2
 (11.355 x weight (kg)) + (7.224 x height (cm)) 
– (4.649 x age) + (135.265 x sexe) – 137.475
 (14.0238 x weight (kg)) + (4.498 x height 
(cm)) – (0.977 x age) + (137.566 x sexe) – 
221.631
Sexe male =1, female = 0






15,4 weight (kg) – 27 height (m) + 717
11,3 weight (kg) – 16 height (m) + 901
8,8 weight (kg) + 1128 height (m) - 1071
13,3 weight (kg) + 334 height (m)+ 35
8,7 weight (kg) - 25 height (m) + 865
9,2 weight (kg) + 637 height (m) - 302






15,3 x weight (kg) + 679
11.6 x weight (kg) + 879
13.5 x weight (kg) + 487
14.7 x weight (kg) + 496
8.7 x weight (kg) + 829
10.5 x weight (kg) + 596
Owen [5] Men
Women
879 + (10,2 x weight (kg))
795 + (7.18 x weight (kg))
Owen FFM [5] Men
Women
22,3 × FFM + 290 = kcal/d
19,7 × FFM + 334 = kcal/d
Müller A [6] 0.047 x weight (kg) + 1.009 x sexe – 0.01452 
x age + 3.21 = REE MJ/d
sexe male = 1, female = 0
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Predictive equations resting energy expenditure.
Name formula Formula




0.07122 x weight (kg) – 0.02149 x age + 0,82
x sexe + 0.731 = REE MJ/d
0.02219 x weight (kg) + 0.02118 x height (cm) 
+ 0.884 x sexe – 0.01191 x age + 1.233 = REE 
MJ/d
0.04507 x weight (kg) + 1.006 x sexe – 
0.01553 x age + 3.407 = REE MJ/d
0.05 x weight (kg) + 1.103 x sexe – 0.01586 
x age + 2.924 = REE MJ/d
sexe male = 1, female = 0
Müller FFM [6] BMI <18.5kg/m2




0.08961 x FFM (kg) + 0.05662 x FM (kg) +
0.667
0.0455 x FFM (kg) + 0.0278 x FM (kg) + 
0.879 x sexe - 0.01291 x age + 3.634
0.03776 x FFM (kg) + 0.03013 x FM (kg) + 
0.93 x sexe - 0.01196 x age + 3.928
0.05685 x FFM (kg) + 0.04022 x FM (kg) + 
0.808 x sexe – 0.01402 x age + 2.818
Sexe male =1, female =0
Women
Men
9.99 x weight (kg) + 6.25 x height (cm) – 4.92 
x age -161
9.99 x weight (kg) + 6.25 x height (cm) – 4.92 
x age + 5
Women
Men
10 x weight (kg) + 6.25 x height (cm) – 5 x 
age – 161




22.5 x FFM (kg) + 209
20.8 x FFM (kg) + 369
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15.0 x weight (kg) – 10.0 x height (m) + 706
11.5 x weight (kg) - 2.6 x height (m) + 877
9.1 x weight (kg) + 972 x height (m) – 834
13.6 x weight (kg) + 283 x height (m) + 98
8.1 x weight (kg) + 1.4 x height (m) + 844









2.84 + 0.0640 x weight (kg) = MJ/d
3.67 + 0.0485 x weight (kg) = MJ/d
2.93 + 0.0499 x weight (kg) = MJ/d
3.43 + 0.0350 x weight (kg) = MJ/d
2.08 + 0.0615 x weight (kg) = MJ/d
3.47 + 0.0364 x weight (kg) = MJ/d
2.88 + 0.0386 x weight (kg) = MJ/d
2.61 + 0.0410 x weight (kg) = MJ/d








14.4 x weight (kg) + 313 x height (m) + 113
11.4 x weight (kg) + 541 x height (m) + -137
11.4 x weight (kg) + 541 x height (m) + -256
10.4 x weight (kg) + 615 x height (m) + -282
8.18 x weight (kg) + 502 x height (m) + -11.6
8.52 x weight (kg) + 421 x height (m) + 10.7










16.0 x weight (kg) + 545
14.2 x weight (kg) + 593
13.5 x weight (kg) + 514
13.0 x weight (kg) + 567
13.7 x weight (kg) + 481
13.1 x weight (kg) + 558
9.7 x weight (kg) + 694
10.1 x weight (kg) + 569
10.2 x weight (kg) + 57
10 x weight (kg) + 577






Women BMI 25-35 
kg/m2
E – 0.1631 – 0.00255 x age + 0.4721 x weight (kg) + 0.2952 x height
(m) = REE MJ/day
E - 0.2630-0.00277 x age + 0.4877 x weight (kg) + 0.3367 x height 
(m) = REE MJ/day
E - 0.1934 – 0.00199 x age + 0.4764 x weight (kg) + 0.0194 x height 
(m) = REE MJ/day
E – 0.0713 – 0.00209 x age + 0.4075 x weight (kg) + 0.3540 x height
(m) = REE MJ/day
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Predictive equations resting energy expenditure.
Name formula Formula
De Luis [13] Men
Women
58.6 + (6.1 x weight (kg)) + (1,023.7 x height 
(m)) – (9.5 x age)
1,272.5 + (9,8 weight (kg)) – (61.6 x height 
(m)) – (8.2 x age)
Bernstein [14] Men
Women
11.02 x weight (kg) + 10.23 x height (cm) –
5.8 age (years) – 1032
7.48 x weight (kg) - 0.42x height (cm) 
-3.0xage (years) +844
Bernstein FFM [11] Men/Women 19,02 × FFM + 3,72 × FM – 1,55 × age + 
236,7 = kcal/d
95
The optimal estimate for energy requirements in adult patients with mitochondrial disease
5
REFERENCES
1. Roza, A.M. and H.M. Shizgal, The Harris Benedict equation reevaluated: resting energy 
requirements and the body cell mass. Am J Clin Nutr, 1984. 40 (1): p. 168-82.
2. Weijs, P.J., et al. Validity of resting energy expenditure predicitive equations in underweight, 
Available from: http://zakboekdietetiek.nl/wp-content/uploads/2015/08/Weijs-REE.pdf.
3. Ramirez-Zea, M., Validation of three predictive equations for basal metabolic rate in adults.
Public Health Nutr, 2005. 8 (7a): p. 1213-28.
from: http://zakboekdietetiek.nl/uitleg-van-de-keuze-voor-formules-voor-het-schatten-
van-de-energiebehoefte/.
resting metabolic rate in healthy nonobese and obese adults: a systematic review. J Am Diet 
Assoc, 2005. 105 (5): p. 775-89.
6. Muller, M.J., et al., World Health Organization equations have shortcomings for predicting 
a new reference standard from a retrospective analysis of a German database of resting
energy expenditure. Am J Clin Nutr, 2004. 80 (5): p. 1379-90.
individuals. Am J Clin Nutr, 1990. 51 (2): p. 241-7.
8. J.M., K. and R. E., How valid are predictive equations to estimate resting energy expenditure
9. Shils M.E, SM, Charterine Ross A, Cabellero B, Cousins RJ, Human Energy Requirements,
in Modern nutrion in Health and Disease. 2006, Lippincott Williams & Wilkins.
10. Gezondheidsraad, Richtlijnen Goede Voeding 2006 achtergronddocument, in 
Gezondheidsraad 2006: Den Haag.
Available from:https://www.gov.uk/government/uploads/system/uploads/attachment_
12. de Luis, D.A., et al., Prediction equation of resting energy expenditure in an adult Spanish
population of obese adult population. Ann Nutr Metab, 2006. 50 (3): p. 193-6.
13. Siervo, M., V. Boschi, and C. Falconi, Which REE prediction equation should we use in normal-




Heidi E. E. Zweers
Debbie Smit
Susanne Leij





To evaluate the effect of an individually tailored dietary intervention on personalized 
goals, body composition (BC), functioning, and quality of life (QoL) in adult patients with 
mitochondrial disease (MD) due to the m.3243A>G mutation.
Methods
In this explorative RCT 39 MD patients were included. The intervention group (n=20)
received an individually tailored dietary intervention during six months. The control 
group (n=19) received usual care during six months (control period) followed by an
individually tailored dietary intervention for the next six months (intervention period).
Nutritional assessment and QoL measurements were performed at three-month 
intervals. Personalized treatment goals of the MD patients were evaluated at 3 and 6
months during dietary intervention. Achievement of the personalized goals was assessed
using descriptive statistics and mixed models. Linear mixed models were used to test the 
effect of the dietary intervention on continuous outcomes.
Results
intervention group compared to the control group. After 3 months of intervention
57% of the goals were achieved. Most goals were achieved for BC, HGS, and gastro-
intestinal complaints. Intervention increased handgrip strength (HGS) (p=0.037), the
vitality component of QoL (p=0.026), and decreased fatigue score (p=0.024) after three 
months of treatment. Effects did not seem to last after 3 months.
Conclusion
An individually tailored dietary intervention is promising to achieve personalized goals of
patients with MD, especially with regard to BC, HGS, and gastro-intestinal complaints. 





Mitochondrial diseases (MDs) are among the most prevalent inherited metabolic 
diseases, with an incidence of approximately 1:5000 live births [1]. The clinical 
the causative mutations affect mitochondrial DNA or nuclear DNA. The most frequently 
reported pathogenic mutation in adults is the m.3243A>G point mutation [1, 2]. Since 
is mainly supportive.
nutrient intake that leads to negative changes in BC, functioning, and clinical outcome. By 
that malnutrition may worsen symptoms in MD, as for instance was shown in a study in 
young MD patients in which an association between nutritional status and mitochondrial 
functioning was observed [7]. Furthermore, it is known that malnutrition causes secondary 
mitochondrial dysfunction, and in this way, it may worsen complaints of MD patients [8].
Previous studies show that adult MD patients have an inadequate food intake with 
various shortcomings and excesses [3], in particular a low intake of protein and increased 
intake of saturated fat and sugar.
comparable with other neuromuscular disorders [9]. It has been shown that the body 
mass index (BMI) and fat free mass (FFM) in MD patients is lower than in the general 
population [4, 10].
With regard to functioning and clinical outcome, MD patients often complain about
myopathy, fatigue, and exercise intolerance, along with an impaired QoL [11, 12]. It has 
been suggested that optimizing nutritional status may improve QoL of MD patients [5],
as was shown in other settings such as cancer cachexia [13].
Until now, no effective treatment for MD exists. Moreover, proving positive effects of 
any kind of intervention on the clinical outcome in this disease is challenging, due to 
the small number of patients and the heterogeneity of the population [14]. Therefore, 
personalized intervention in these patients might be more appropriate. To date the
this explorative randomized controlled trial (RCT) was conducted to explore the effect
of an individually tailored dietary intervention on personal goals in adult mitochondrial 




Standard protocol approvals, registrations and patient consents
This study was conducted in accordance with good clinical practice and the Declaration 
of Helsinki. The Medical Ethics Committee of the Arnhem and Nijmegen region approved
the study protocol and written informed consent was obtained from every patient. The 
study was registered as DINAMITE study in ClinicialTrials.gov (NCT02286856).
Study design
The DINAMITE study comprised a single center, explorative, 2-armed, randomized
controlled dietary intervention study. Randomization for the intervention or control group 
The intervention group received an individually tailored dietary intervention for six months
period) immediately followed by individually tailored dietary intervention for six months.
Both the intervention and control group were evaluated at baseline (t=0), three (t=1), and 
six months (t=2). In addition, the control group was evaluated at nine (t=3) and twelve
months (t=4) during their intervention period.
Patients
Eighty eligible patients with MD due to the 3243A>G mutation in mitochondrial
DNA from the Radboud Centre for Mitochondrial Medicine cohort [2] were asked to 
participate in the study. They were allowed to participate when they were at least 18 
years of age, had no medical contraindication to undergo Nutritional Assessment after 
overnight fast, had no pacemaker nor did they suffer from claustrophobia. The severely
malnourished patients with a BMI below 17.5 were not included because of ethical
considerations. Patients were measured between 2014 and 2017.
Dietary intervention
All patients received a written personal diet schedule in which the metabolic dietician
made the translation from the nutrient requirements into food products. The diet 
schedule was based on a healthy diet with whole grain, low sugar and saturated fats. 
Personal food preferences were taken into account to enhance compliance. Energy advice 
was based on individually measured energy requirements. When patients wanted to lose 
weight the daily energy intake was reduced with ±250 Kcal a day to ensure slow weight 
loss en prevent loss of muscle mass. The energy restriction consisted out of cutting extras
like sweets, alcohol and snacks. When patients wanted to gain weight a minimum of 




with oral nutritional supplements. Individual protein requirements were calculated 
based on ideal body weight and nutritional status [15]. The patients with malnutrition 
based on low Fat Free Mass Index (FFMI) [16] were advised 1.2 grams of protein/kg 
ideal bodyweight. Patients with proteinuria were allowed a maximum of 0.8 grams of 
protein/kg bodyweight. Micronutrients were advised according to the RDA and if it was
not possible to meet requirements with normal products supplements were advised. 
fullness, nausea and dysphagia were advised to adapt the consistency of nutrition to a
more liquid form. This advice was also given to the patients who eat slow and had a low 
nutrient intake due to fatigue. In the patients with air related gastrointestinal problems
addition, practical advice was given on how to cook healthy when having less energy.
Personal goals
The personalized treatment goals were determined and evaluated by the patient in
consensus with his/her dietician based on the results of the Nutritional Assessment. 
Goals of patients were determined for seven variables: weight, FFM, fat percentage, 
“keep stable”, “decrease/increase” or “not applicable”. See supplement 1.
Measurements
All measurements were performed according to the corresponding standard operating 
procedures after an overnight fast. To evaluate protein intake, BC, and functioning, 
Nutritional Assessment was performed every three months. In addition, QoL was
measured and the risk of malnutrition was assessed with the Patient-Generated 
Subjective Global Assessment (PG-SGA) [17]. NMDAS and heteroplasmy levels were 
The following Intake and requirements were measured:
- Indirect Calorimetry (IC): at baseline, the resting energy expenditure (REE) [18] 
was measured by IC (Cosmed Quark RMR®).
- Physical activity Level (PAL): PAL was determined as the average total metabolic 
equivalents (METS) measured by an accelerometer (Sensewear mini ®) that was 
carried by the patients during one week [19].
- Nutritional intake: mean daily nutritional intake was calculated by means of a 3-day
food record. The protein intake (g/day) was calculated in a standardized manner
using the nutrition calculation program Madows® [3].
The following BC measurements were taken:
- Anthropometry: Height (cm), weight (kg), waist circumference (WC) (cm), triceps 
skinfold thickness (mm), upper arm circumferences (cm) and upper arm muscle
circumference (cm) [20] were measured.
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- BC: The FFM was estimated by single frequency bioimpedance analysis (Bodystat®) 
at 50 Hz, fat percentage, and fat free mass index (FFMI) were calculated with the 
formula of Kyle [21].
The following functioning parameters were measured:
- Objective variable hand grip strength: HGS (kg) was measured using the Jamar®
dynamometer.
- Subjective variable fatigue: Fatigue was assessed with the short Checklist Individual
Strength (CIS)-fatigue questionnaire [22].
- Gastrointestinal complaints: Nine questions of the gastrointestinal questionnaire 
were used [23]. Frequency of the symptoms was scored on a 7-point Likert scale.
The following QoL data were collected:
- The subjective QoL was assessed using the RAND-36 (SF-36) questionnaire [24]. 
This patient-reported survey provides a score for eight different dimensions: vitality, 
physical health, pain, general health, role functioning physical, role functioning 
emotional, social functioning, and mental health.
Data analysis
All data were collected on a paper case report form and doubly entered into the online
Castor® database to minimize entry mistakes. Statistical analysis was performed using 
SPSS statistics (IBM, version 24).
Patient characteristics at baseline were compared with applicable references values [16, 
17, 20, 25-28]. Baseline characteristics were reported as means ± standard deviation 
(SD) or as the exact number with percentage of the total population. Normal distribution
of the variables was assessed by Shapiro-Wilk tests. Independent t-tests and Mann-
Whitney U tests were performed at baseline to check for between group differences 
for continuous variables. Chi-Square test was used to test the distribution of categorical 
characteristics across the intervention and the control group.
The number of achieved personal goals was assessed using descriptive statistics. For each
was assessed, and how many goals were achieved after 3 and 6 months. For the whole 
of these goals had been achieved was assessed. Because of the hierarchical structure of
our study (personal goals nested within patient) we performed multilevel (mixed model) 
analyses. Difference in proportion of achieved goals between control and intervention 
difference in proportion between control group and intervention group and difference
in proportion within the control group between control period and intervention period 




were the same as the goals in the intervention period. In this analysis the gastro-intestinal 
and other goals could not be included because no data of achieving these goals in the 
control period was available.
Linear mixed models were performed using a time by group interaction to test the
longitudinal effect of the dietary intervention on continuous outcomes: protein intake, 
weight, fat percentage, fat free mass index, upper arm muscle circumference, WC, HGS,
fatigue, and the eight domains for QoL. Two different analyses were performed using








12 months). In the mixed models, the periods of the measurements and the control or
suggested a change over time, mixed model pairwise comparison of time points was 




Eighty MD patients were approached, 40 were willing to participate in this study and
signed informed consent (Figure 1). Patient characteristics are shown in Table 1 and were
similar in the control and intervention group. For detail individual results see supplement 1. 
No harm or unintended effects were observed.




Table 1. Patients characteristics.






Age (years) 47 ± 13 47 ± 14 46 ± 12
Gender Female 32 (82) 16 (80) 16 (84)
BMI (kg/m2)1 23.7 ± 4.7 25.0 ± 7.0 22.1 ± 5.6
Underweight 2 (5) 1 (5) 1 (5)
Normal 21 (54) 9 (45) 12 (63)
Overweight 12 (31) 7 (35) 5 (26)
Obesity 4 (10) 3 (15) 1 (5)
NMDAS score 18 ± 10 16 ± 10 19 ± 10
12 (32) 5 (26) 7 (37)
NMDAS <20 26 (68) 14 (74) 12 (63)
Heteroplasmy UEC 50 ± 21 45 ± 23 54 ± 19
Phenotypes
MIDD 20 (51) 10 (50) 10 (53)
Myopathy 17 (44) 9 (45) 8 (42)
MELAS 2 (5) 1 (5) 1 (5)
Indirect Calorimetry (kcal) 1443 ± 240 1507 ± 266 1376 ± 194
Exercise METS 1.4 ± 0.3 1.4 ± 0.2 1.5 ± 0.3
Sleep duration (h:mm) 7:41 ± 1:00 7:53 ± 1:07 7:29 ± 0:52
Energy intake (kcal) 1783 ± 453 1806 ± 478 1759 ± 437
Protein intake (gram) 71 ± 17 70 ± 14 71 ± 19
Low 14 (36) 8 (40) 6 (32)
Fat percentage (%) 34.8 ± 7.1 35.3 ± 7.0 34.2 ± 7.3
High 34 (87) 18 (90) 16 (84)
FFMI (kg/m2) 15.7 ± 2.3 16.2 ± 2.3 15.3 ± 2.1
Low 20 (51) 9 (45) 11 (58)
Handgrip strength (kg) 24 ± 10 24 ± 8 24 ± 11
Low 33 (85) 18 (95) 15 (75)
UAMC (cm) 22 ± 23 22 ± 3 22 ± 3
Low 13 (33) 6 (30) 7 (37)
WC (cm) 90 ± 14 91 ± 14 88 ± 13
High 28 (72) 16 (80) 12 (63)
Fatigue score 40 ± 8 41 ± 9 38 ± 6
Fatigue 35 (90) 16 (84) 19 (95)
PG-SGA score 4 ± 3 4 ± 3 4 ± 3
risk for malnutrition 21 (55) 11 (58) 10 (53)
Data are shown as mean ±SD, number (%) or otherwise stated. 1: shown as median ± IQR. BMI: Body 
Mass Index: Underweight <18.5 kg/m2, Normal 18.5-24.9 kg/m2, Overweight 25.0-29.9 kg/m2, Obesity 
>30.0 kg/m2, NMDAS: Newcastle Mitochondrial Disease Adult Scale, UEC: Urinary Epithelial Cells, 
MIDD: Maternally Inherited Diabetes and Deafness, MELAS: Mitochondrial myopathy, Encephalopathy,
Lactate Acidosis, and Stroke-like episodes, METS: Metabolic equivalents, Protein Intake (g/day):% of the
2) [16],
UAMC: Upper Arm Muscle Circumference (cm) [29], WC: Waist Circumference (cm) [26], HGS: Hand 




more goals were achieved in the intervention group compared to the control group
(respectively OR 2.6 95% CI 1.4-5.1 and OR 2.0 95% CI 1.0-4.1) (Table 2). Within the
intervention period (Table 3). A total of 182 individual goals were determined at the 
of the goals (72%) aimed at changing an outcome variable, while the remainder aimed at 
the whole patient group, of which 60% aimed to decrease or increase the variable, and
variables are shown. Most goals were achieved for BC, HGS, and gastro-intestinal
complaints. In total, more goals were achieved after three months (57%) compared to six
months (43%) (Figure 2B). All but one patient (97%) achieved at least one personal goal.










47 (52) 21 (29) 2.6 (1.4-5.1) p= 0.004
Achieved goals
after 6 months
46 (52) 25 (35) 2.0 (1.0-4.1) p= 0.002
Table 3. Percentage achieved goals after 3 and 6 months: Comparison within control group









26 (37) 21 (29) 1.4 (0.7-2.8) p=0.35
Achieved goals
after 6 months





at start (left) and after 3 months (right). Data about the achievement of the goals are presented
as the mean percentage of the total goals of the corresponding variable (B) after 3 months (left)
and after 6 months (right). n=38
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Effect of individually tailored dietary intervention
Full data available in supplement 1.
weight, fat percentage, FFMI, upper arm muscle circumference, or WC compared to 
the control group.
Functioning: The individually tailored dietary intervention increased HGS (p=0.037) in 
the intervention group compared to the control period (Figure 3B). Secondary pairwise 
three months of intervention for the control group but decreased again in the last three
comparing the intervention group with the control group (six and twelve months). The
secondary analysis showed that fatigue score decreased (p=0.024) after three months 
of intervention in the intervention group compared with the control group (Figure 3C).
(six months, p=0.026) and for the control period compared to intervention group and
intervention period (twelve months, p=0.037) (Figure 3D). For the other domains for 
Figure 3. Effect of individually tailored dietary intervention and time comparison between inter-





tailored dietary intervention on achieving personal goals in MD patients carrying the
achieved in the intervention group compared to the control group. Even in this small
group of patients we observed a consistent effect on objective and subjective functional 
outcome parameters: HGS, fatigue and the vitality component of the QoL, ruling out 
coincidence due to multiple testing. The results are highly relevant and in line with effect 
of diet counselling in other diseases with high malnutrition incidence. This suggests that 
a tailored dietary intervention is promising treatment strategy in a currently not curative 
This corresponds well with frequently occurring symptoms in this patient population 
[30, 31]. In the current study, 57% of the treatment goals were achieved within three
months of the dietary intervention. This is in line with a study in obese patients (43%
personal goals achieved) [32]. To obtain a successful dietary intervention it is often crucial 
achievement of 57% of the goals in our study can be considered as a positive result. More 
importantly, these data show that at the individual level it is possible for MD patients to 
improve their BC and FFM, which is in contrast to other neuromuscular disorders [34].
The patient characteristics at baseline show that malnutrition frequently occurs in this
patient category, but that heterogeneity is present. The PG-SGA scores suggest that 
Analyses of the goals demonstrated that this nutritional intervention was successful in
achieving at least one goal in 97% of patients. This implies that also patients who do not
When analysing the personal goals, a relevant improvement in BC was demonstrated on a
group level, however no effect of the intervention on protein intake and body composition
was observed. Non-compliance might be an issue here, as well as the relatively small 
patient population, heterogeneity, the non-standardized intervention, as well as inter-
dependency of various variables. The fact that no change in weight at group level was
observed might be due to the existence of contradicting goals in the population: losing 
and gaining weight goals. Concerning protein intake only half of the patients (n=20) were 
advised to increase their intake and most of them (n=16) actually did. This seems a relevant 
some patients had already received dietary advice prior to entering the study and 
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Multiple factors may underlie our results, including improved nutritional intake and 
improved nutritional status. There were no differences in activity levels between groups 
that might explain these results. Generally, it is known that lifestyle changes and focus on 
healthy eating can make healthy people feel more energetic. This effect seems to apply
on the MD population as well.
other domains for QoL. That this might be due to the effect of personal attention is
corroborated by the fact that in the control group QoL improved as well, especially in
Our results suggest that the individually tailored dietary intervention was most effective 
possible reason for this is that these patients are highly motivated with a good compliance
directly after the advice is given, but that this drive decreases afterwards, similar to 
observations in this setting in other populations [35]. The positive results patients
observed in patient characteristics between patients who achieved more than 50% of 
A limitation of this study was that it, for obvious reasons, could not be conducted in a
blinded manner. The fact that the severely malnourished patients were not included was
also a drawback because a larger effect of dietary intervention would be expected in 
these patients. Furthermore, that gastrointestinal complaints could not be analysed on a 
group level was a limitation, because of the non-continuous nature of this variable. Finally,
the fact that there is no gold standard to measure nutritional status was a drawback 
because we had to categorize our primary outcome variable into many sub variables
is debatable. For patients achieving individual goals that they choice themselves seems 
A strong aspect of this study is the way the personalized health care principles were 
implemented in an explorative RCT. Although the individually tailored nature of 
the intervention hindered evaluation on the population level, it was shown that the 
individually set goals were more frequently achieved after the intervention compared to 
with one dietician is a strong point [36], as well as the use of various validated and well-
known scales and assessment tools. The fact that all patients were treated in the same





This study demonstrates that an individually tailored dietary intervention supports MD 
functioning and QoL. The effects in this explorative RCT were largely short-lasting but 
studied further preferably in a RCT with a single intervention and with a better outcome 
variable than the llikert scale that was used in this study. Nutritional assessment and 
personalized interventions should be considered in all MD patients. Using personal goals
of individual patients is valuable for evaluating the effect of a nutritional intervention.
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Effect of individually tailored dietary intervention group analyses Quality of Live.
Intervention group Control group
Control period Intervention Period
T0 T1 T2 T0 T1 T2 T3 T4
Physical functioning 59 66 67 59 64 64 58 65
upper limit 70 77 78 70 75 77 70 78
lower limit 47 56 56 49 53 51 47 53
Role functioning physical 40 46 42 37 46 41 45 63
upper limit 53 56 51 46 55 50 51 76
lower limit 28 36 33 29 37 37 38 49
Bodily pain 61 66 61 63 60 63 61 62
upper limit 73 78 73 73 70 72 70 72
lower limit 48 54 49 53 50 54 52 52
General health 42 43 42 39 42 28 36 34
upper limit 54 55 54 47 50 36 45 44
lower limit 30 31 31 31 33 20 27 25
Vitality 41 48 42 49 44 42 49 45
upper limit 50 58 51 56 52 50 56 52
lower limit 32 38 33 42 36 34 41 38
Social functioning 53 59 57 67 65 60 68 69
upper limit 63 72 70 77 75 72 78 77
lower limit 44 47 45 58 54 48 58 59
Role functioning emotional 51 60 46 63 65 66 63 67
upper limit 66 72 56 76 78 80 76 79
lower limit 37 48 36 49 53 37 51 54
Mental health 64 66 70 75 75 70 77 75
upper limit 73 76 79 82 82 81 84 84
lower limit 55 57 61 68 68 60 69 67



























































































































































































































































































































































































































































































































































































































































































































































No curative therapy for mitochondrial disease (MD) exists, prioritizing supportive 
treatment for symptom relief. In animal and cell models ketones decrease oxidative stress, 
increase antioxidants and scavenge free radicals, putting ketogenic diets (KDs) on the list
of management options for MD. Furthermore, KDs are well-known, safe and effective 
treatments for epilepsy, a frequent symptom of MD. This systematic review evaluates 
Methods
We searched Pubmed, Cochrane, Embase and Cinahl (November 2020) with search 
course were excluded. The remaining studies were included in the qualitative analysis.
Results
(one controlled trial (n = 5), 15 case reports). KD led to seizure control in 7 out of 8
cases and improved muscular symptoms in 3 of 10 individuals. In 4 of 20 cases KD 
reversed the clinical phenotype (e.g. cardiomyopathy, movement disorder). In 5 adults
with mitochondrial DNA deletion(s) related myopathy rhabdomyolysis led to cessation 
of KD. Three individuals with POLG mutations died while being on KD, however, their
survival was not different compared to individuals with POLG mutations without KD.
Conclusion
should be considered in individuals with MD and therapy refractory epilepsy, while it is 
contraindicated in mitochondrial DNA deletion(s) related myopathy. When considering 
KD for MD the high rate of adverse effects should be taken into account, but also 
spectacular improvements in individual cases. KD is a highly individual management 
option in this fragile patient group and requires an experienced team. To increase 
knowledge on this -individually- promising management option more (prospective) 




Mitochondrial diseases (MDs) are a heterogenous group of inborn metabolic diseases 
caused by defects in the genes encoding mitochondrial proteins that are required for ATP 
production from oxidation of substrates via the tricarboxylic acid cycle and the oxidative 
phosphorylation (OXPHOS). Underlying pathogenic variants can be found in nuclear
or mitochondrial DNA (mtDNA) [1, 2]. Currently more than 295 different disorders 
are known [2]. While every single disorder is rare, the combined estimated lifetime 
risk of 235 investigated nuclear encoded autosomal recessive MDs (corrected for the 
beta-oxidation defects), was calculated 18.74/100,000 based on the global Genome 
Aggregation Database (gnomAD) equalling e.g. 3,260 affected individuals/17.4 million 
Dutch inhabitants [3]. Virtual all the extremely heterogeneous symptoms can occur with
onset at all ages, but typically tissues with high energy requirements like skeletal/heart
muscle and brain are mainly affected. Currently no curative treatment is available, making
the supportive management for symptom relief priority.
Given the key role of mitochondria in energy metabolism and the importance of vitamins
and co-factors for proper mitochondrial function, nutritional interventions are an integral 
component of daily management [4-8]. Moreover, nutritional interventions focusing on 
nutritional status or gastro-intestinal complaints have been shown effective [4, 5].
β
uses grams of fat: grams of carbohydrate plus protein-ratio (e.g. 4:1 or 3:1) in every meal.
Fat can be (mainly) given as medium-chain triglyceride (MCT), this subtype is called MCT-
KD. As MCT-fats are converted easier into ketones than longer chain fatty acids, ketosis 
can be achieved more easily, and more carbohydrates can be consumed. In contrast, the
restricting the amount of fat and protein [9-11].
KDs have been proven successful in the treatment of intractable epilepsy and are 
generally well tolerated and safe [10, 12, 13]. It is thought that KDs exert their positive
effect (among others) via stimulation of mitochondrial biogenesis, improvement of 
mitochondrial function and decrease of oxidative stress [14-17] and therefore have
been implemented in some cases with MD and epilepsy [13, 18]. There are also studies 
20-24]. Of note, while it was previously assumed that the liver provides ketone bodies to 
the brain, astrocytes itself have shown to be ketogenic cells. This astrocyte ketogenesis 
might control the survival/death decision of neural cells at least twofold. By scavenging
of these metabolites and their derivatives (e.g. ceramide) on brain structure and function. 
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Further, by acting directly as pro-survival metabolites, the ketone bodies may preserve 
neuronal synaptic function and structural stability [25].
When a diet provides only small amounts of glucose, hormones as glucagon inhibit
glycolysis and stimulate ketogenesis. These ketone bodies can only be produced in 
the liver and in astrocytes and provide the mitochondrial OXPHOS with a substrate
dinucleotide (FADH2) than the glycose pathway and therefore fat has a potential
However, nicotinamide-adenine-dinucleotide (NADH) is still formed from all substrates
and complex 1 is never completely bypassed (Figure 1).
pyruvate to acetyl-CoA and KDs are the pathomechanism based therapy as ketones, 
contra indication for KD as gluconeogenesis is impaired and affected individuals depend 
on nutritional glucose.
Figure 1. Metabolic pathways of carbohydrates, fat and ketone bodies in energy metabolism
ATP = Adenosine triphosphate, C = respiratory chain complex, PDHC = Pyruvate Dehydrogenase
Complex, PC = Pyruvate Carboxylase, TCA Cycle = Tricarboxylic acid cycle also called citric acid cycle.
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Taken together, KDs are an interesting management option for MD that needs further 
of KD for MD.
METHODS
Search strategy
This systematic review was conducted according to the Preferred Reporting Items for 
studies using medical subject headings (MeSH) and text words related to KD and MD (see 
Supplement 1). The databases searched were: Pubmed, Cochrane, Embase and Cinahl
(November 2020) without any search limits. The search strategy for Pubmed was generated 
together with a specialist librarian and accordingly amended for the other databases.
Study selection
Two authors (HZ, AvW) independently screened and selected the papers using Rayyan® 
[29]. Eligibility criteria were: cases with MD using a KD and English language. The same
authors reviewed full texts of these selected papers independently, according to exclusion
criteria. Disagreements were resolved by consensus and discussion with a third author
(SBW). Exclusion criteria were: i) cases without genetically proven MD [1, 2], ii) cases
and iiii) cases without data of effect on clinical phenotype before and under treatment.
including the low glycaemic index diet are not likely to achieve ketosis and therefore 
cases treated with these diets were excluded.
Reference lists were reviewed for additional publications.
Outcome measures
The primary outcome was the effect of KD on clinical phenotypes (epilepsy, muscle 
involvement, tonus dysregulation (muscular hyper- or hypotonia), movement disorders,
developmental delay and intellectual disability (DD/ID), other individual signs and symptoms)
Data extraction and quality appraisal
Two authors (HZ, AvW) extracted data and checked the data for completeness. A
third author (SBW) checked all articles again to ensure correct interpretation of data.
Discrepancies were resolved through discussion and consensus.
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We used The Oxford Levels of Evidence 2 [30] scoring to assess study quality as well as 
The Risk Of Bias In Non-Randomized Studies – of Interventions (ROBINS-I) assessment 
tool [31]. No studies were suitable for pooling of the results and therefore a narrative
analysis is presented.
RESULTS
which 17 papers reporting 20 cases were included in the detailed analysis. All data are 
summarized in Table 1 and Figure 3. Of note, (multi)vitamins and other food supplements 
were reported in many of the included cases (see Table 1 for details). With exception of 
one case (TPK1 [33]) clinically not responding to thiamine supplementations, none of
the reported vitamins or co-factors were pathomechanism based treatment options and
therefore were not taken into account in our analysis.
Records identified through 
database searching 
Pubmed (n) 470 
Embase (n) 616 
Cochrane (n) 14 
Cihahl (n) 49 

























identified through other 
sources  
n = 3   
Records after duplicates 
removed  
n = 694 
Total records screened 
n = 694 
Records excluded 
n = 605 
Full-text articles assessed 
for eligibility 
n = 89 
Full-text articles excluded  
n = 72 
Studies and reason for exclusion 
listed in supplement 2 
Studies included in 
qualitative synthesis 
n = 17  
 20 cases 
Figure 2. detailing the search strategy.
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TWNK, mult mtDNA del (39)
TWNK, mult mtDNA del (39)
TWNK, mult mtDNA del (39)
Figure 3. Summary of positive and negative effects of ketogenic diet in 20 cases with genetically 
proven mitochondrial disease.
Figure 3 visualises the negative effects and adverse events on the left and the positive effects (on the
right) of ketogenic diet in 20 cases with genetically proven mitochondrial disease.
*temporary effect **cases with reported treatment-withdrawal effect B/B = bladder and bowel, 
CPEO = chronic progressive external ophthalmoplegia , del = deletions, HC = head control, mult = multiple
deletions in mitochondrial DNA, MRI = magnetic resonance imaging, mtDNA = mitochondrial DNA, 
SLE= stroke like episodes, SM = skeletal muscle, TD = tonus dysregulation
Case characteristics
Of the 20 cases (12 female), 16 had a nuclear DNA and 4 a mtDNA related mutation.
Of note 3 of the nuclear variants (TWNK) lead to multiple mtDNA deletions. The ages
at start of KD ranged between 0 and 62 years (1 neonate (aged 7 days), 2 infants (9 and 
10 months), 11 children (1.3 to 16 years), 6 adults (aged 22 to 62 years). Eight individuals 
(8/20), were described as having epilepsy. In 10/20 individuals muscle involvement
(cardiomyopathy, muscle weakness, exercise intolerance, ptosis) was reported, 7/20 were 
described having tonus dysregulation, and for 5/20 cases movement disorder(s) (ataxia, 
dystonia) were reported. In 10/20 cases DD/ID was reported. Other reported symptoms 
were visual problems, respiratory distress, headaches/migraine, failure to thrive, feeding




The general study quality was low, with 15 case reports (category 4) and one controlled 
trial with 5 adult participants (category 3b). The risk of bias in the trial was scored as low.
Interventions
Eleven cases followed a classical KD, 8 cases a MAD. For one case the composition of 
the KD was not detailed, however, this case was included as achievement of ketosis was 
documented. For a total of 14 cases achievement of ketosis was reported. The total diet
duration of all 20 cases together was > 22 patient years, the median diet duration was 4 
months (range 4 days -9 years). The main reasons for discontinuation of the diet (n=12)
were death (n=3) [34-36] and other AEs (n=7) [37-40]. In one case the daily constraints
hearing [42] lead to cessation after 2 years and 4 months, respectively.
Primary outcomes
Effect of KD on epilepsy
In 7/8 cases with uncontrolled epilepsy seizure control was achieved with KD (5 seizure 
free, 1 reduction of seizures and 1 “stabilisation” of status epilepticus). In 4 of these cases 
the effect was only temporary (lasting a few weeks to 7 months). In one case no positive
effect of the KD on epilepsy was reported, and the KD was stopped after 5 days due to
metabolic acidosis.
Effect of KD on other clinical signs and symptoms
Skeletal and heart muscle
In 3/10 cases with muscle involvement KD had a positive effect. This was the return of 
bladder and bowel control, and the ability to walk with assistance [34], and the complete 
resolve of chronic progressive ophthalmoplegia (CPEO) and ptosis [41]. In the third case, the
3-year-old individual regained walking abilities with improved lower limb muscle strength
after one year of KD and normalisation of septum thickness of hypertrophic cardiomyopathy 
after 3 years of KD. This effect was sustained at the last follow up at age 11 years (total 
8 years of KD) [43]. A negative effect was observed in 6/10 individuals. Five of these six 
individuals experienced rhabdomyolysis, headache and fatigue leading to cessation of KD 
after 4 to 11 days [39] and in one case progressive muscular hypotonia with swallowing
Tonus dysregulation
Tonus dysregulation was reported to improve in 3/7 cases, while in one case progressive
muscular hypotonia was only reported after the KD was started [38]. In all 3 cases head 
control improved [33, 44, 45] and one case additionally showed improved stability of 




In one case the paroxysmal ophisthotonic dystonia completely resolved for more than 
5 years of follow-up [46]. In one individual the ataxia did not improve [47], in the other 3 
cases no further details were provided [34, 35, 41].
Developmental delay/Intellectual disability
In 3/10 cases with DD/ID a positive effect of KD was reported (e.g. increased verbal 
response and abilities, social interaction, improved memory) however no data of 
formal psychological or developmental testing were presented [33, 34, 45]. The other 
publications did not provide further details.
Other
An improved oral food intake [33], improved weight gain and growth [43] and hair growth 
in an individual with alopecia [42] were reported in one case each.
Treatment-withdrawal effect
In 3 cases a treatment withdrawal effect was demonstrated. In the case where KD had 
resulted in hair growth, this was lost again 6 months after cessation of KD [42]. In the 
individual where KD led to disappearance of the dystonic-opisthotonic episodes within 
5 days for 5 months, these reoccurred within a few days when the KD was stopped and 
disappeared again 4 weeks after reintroducing KD [46]. In the case where CPEO and 
ptosis resolved within days and remained absent for 2 years on KD, the ptosis partially 
reoccurred upon “relaxation” of the diet [41].
Adverse events
In 13/20 individuals AEs were reported (Table 1). In one study [39] all 5 adult participants with
mitochondrial myopathy (2 mtDNA single deletion, 3 TWNK/multiple mtDNA deletions) 
stopped MAD within 4- 11 days because of rhabdomyolysis, headache and tiredness.
Three individuals, all with POLG-related Alpers syndrome, died during KD (at the ages 
of 46 months [35], 66 months [34] and 16 years [36]) of respiratory failure (n = 2) or 
paralytic bowel obstruction (n = 1). This was 3 months (n = 2) [35, 36] and 35 months
[34] respectively, after presentation.
Other AEs that lead to immediate cessation of the KD were severe lethargy, which
occurred after 5 months of KD in one case [40] and lactic acidosis (after 5 days of KD)
in one other case [37]. Of note, two individuals in two reports remained on KD despite
AEs. In one case because of successful seizure reduction despite a sudden deterioration 
of visual acuity, ptosis and general weakness after 6 months of KD [47] and in one case 
the resolve of the movement disorder outweighed the worsening seen on MRI [46]. In
one individual [38] who suffered from weight loss, regression and hypotonia the KD




From the 12 cases with reported MRI abnormalities for only 2 cases MRI details were 
provided after KD initiation. In one case a resumed myelination during KD was observed
[45], while in the second the MRI worsened [46]. Interestingly in the latter case, the 
movement disorder had completely resolved, and the patient was reported to develop
age-adequately. In 7 cases lactic acidosis was reported which normalised in one [40], 
worsened in one [37] and did not change in 2 cases [38, 41]. For the remaining 3 cases 
no details were reported [43, 44, 47]. Two individuals with POLG mutations had mildly
elevated liver function tests before KD initiation [34, 35]. In one case these remained
elevated [34], in the other case no details were provided [35]. In one individual a transient, 
four day long, increase in liver function tests occurred [36].
DISCUSSION
Despite identifying 694 studies using our search strategy, only 20 cases (one controlled 
reports on KD for MDs must present a minimum of “common data elements” (in line with
the data shown in Table 1) describing the composition of KD as well as the clinical effect
including adverse events.
KD is effective for seizure control in MD
KD was highly effective and led to seizure control of therapy refractory seizures in 7 
of 8 MD cases, at least temporarily. KD was stopped only after 5 days in the 8th case 
and it remains elusive if adaptation of the KD would have overcome the occurring lactic 
acidosis and would have led to seizure control. The number of cases does not allow 
25% becoming seizure free on 4:1 classical KD/ MAD [10]).
KD might be effective for the treatment of other signs and symptoms of MD in
individual cases, but is contraindicated in mtDNA deletion(s) related myopathy
In 12/20 cases KD was initiated for other indications than epilepsy. In 5 adults with 
mitochondrial myopathy KD was stopped due to AEs in all participants [39]. However, 
improvement on muscle strength and in 6-minute walking test in three of four patients 
after 2.5 years of follow up after cessation of KD.
In the remaining 7 pediatric cases, 5 improved clinically [33, 41-43, 46], mainly concerning 
muscle symptoms. Especially the well reported treatment-withdrawal effect in three
cases (start/stop hair growth, resolving/reoccurring ptosis or movement disorder) 
illustrates the potential for KD in individual management of MD. Of note, in one case
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hypertrophic cardiomyopathy was completely resolved on KD and sustained without
any additional medication [43]. The authors discuss that ketone bodies may have
modulated cardiac metabolism. This is in line with the data suggesting that in heart failure 
carbohydrates may contribute to declining contractile function. A role for ketones both 
in signalling as well as an energy source is suspected to underlie this [48].
Safety aspects of KD for MD
AEs occurred 65% of MD cases during KD. This percentage is comparable with studies on
(22/34 = 65%) [13, 18]. AEs of KD reported in literature for refractory epilepsy are 
mainly gastrointestinal complaints rarely leading to discontinuing of the diet, but also 
lethargy and acidosis have been reported [10, 12].
The 3 children with MD that died (aged 66 -192 months) while being on KD all had POLG-
related Alpers disease, an early lethal disorder with a median age at death of 16 (range 
1 - 181) months [49]. Hence, their age of death is comparable. Moreover, the median
survival after presentation is reported to be 5 (0.5 -181) months without KD [49] and
was 3 (n=2) and 35 months, in the cases with KD reviewed here.
but is in line with the natural disease course of childhood onset MD.
Practical recommendations
in refractory epilepsy [12, 13, 50] in general. This pathomechanism approach assumes 
that fatty acids compared to carbohydrates produce more FADH that can enter complex
II [13, 19, 50, 51] and hence allows (partial) bypassing of complex I. However, as outlined 
in the introduction (Figure 1), NADH is still formed from all substrates and complex I is
never completely bypassed.
Our study did solely include cases with known genetic background as increasing
seen in MD but also in other genetic diseases especially if measured in muscle specimen 
other therapy refractory epilepsies. However, from our results we conclude that KD 
should be considered in MD patients with therapy resistant epilepsy.
Given the risk of AEs KD should be initiated by a team experienced with both MD and
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line with the general guideline on KD). From our data we cannot conclude after which 
of KD, in analogy to KD for intractable epilepsy [53]. Whether classic KD or MAD is
superior is unknown and an individual top-down (start KD 4:1) or bottom up approach 
(start with MAD) should be weighed and discussed with patient and/or parents.
An appraisal for high fat diets
KD for MDs are probably not only based on ketogenesis and energy expenditure from 
ketone bodies [23, 54]. Two studies that did not met our inclusion criteria, reporting 
improved maximal workload and muscle force under high fat diet [55, 56]. Another n=1 
trial reported a high fat diet improving the endurance in a bicycle test when compared
to a high carbohydrate diet in one adult (TMEM126B) [51].
There is further interesting evidence to encourage human studies on high fat diets for 
resulted in protection from cell death caused by glucose withdrawal presumably based
on fatty acid induced stimulation of mitochondrial biogenesis. Second, the study of a 
down disease progression regarding major neurodegenerative symptoms and cerebellar
atrophy [57].
More studies on high fat diet in humans reporting the aforementioned common data 
elements are necessary to draw conclusions. However, it also has to be considered that
a high-fat diet could downregulate genes involved in the mitochondrial respiratory chain 
and could thereby worsen the mitochondrial dysfunction [58].
CONCLUSION
KD should be considered in individuals with MD and therapy refractory epilepsy,
while mtDNA deletion(s) related myopathy is a contraindication (as well as Pyruvate
patient group and requires an experienced team. To increase knowledge on this 
-individually- promising management option more (prospective) high quality studies 
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Study / Year Reason for exclusion
Barzegar 2007 [1] No genetic mitochondrial diagnose
Ait-El-Mkadem 2017[2] Unknown diet composition
Al Madhoun 2019 [3] Unknown diet composition
Banka, 2014[4] Unknown diet composition
Bernard 2008 [5] Wrong population: not on ketogenic diet
Bjorkman 2015 [6] No clear or minimal outcome data
Brivet 2003 [7] High fat diet
Cardenas 2010 [8] Unknown diet composition
Emperador 2019 [9] Wrong study type: cell study
Fahrner 2016 [10] No genetic mitochondrial diagnose
Friederich 2020 [11] No clear or minimal outcome data
Fukao 2019 [12] Wrong population
Garcia-Cazorla 2005 [13] No clear or minimal outcome data
Grazina 2007[14] Unknown diet composition
Gropman 2018 [15] Letter to the editor
Guilliams 2013 [16] Letter to the editor
Han 2017 [17] No clear or minimal outcome data
Habarou 2017[18] Unknown diet composition
Hasan-Olive 2019 [19] Wrong study type: animal study
Hildick-Smith 2013 [20] No clear or minimal outcome data
Hussain 2016 [21] Wrong population
Joshi 2016 [22] No genetic mitochondrial diagnose
Jung 2012 [23] No genetic mitochondrial diagnose
Kang 2006 [24] No genetic mitochondrial diagnose
Kang 2007 [25] No genetic mitochondrial diagnose
Khan 2012 [26] Unknown diet composition
Kim 2012 [27] No genetic mitochondrial diagnose
Klepper 2003 [28] Not written in English
Klepper 2004 [29] Not written in English
Kwong 2019 [30] No genetic mitochondrial diagnose
Lee 2008 [31] No genetic mitochondrial diagnose
Lee 2010 [32] No genetic mitochondrial diagnose
Lee 2016 [33] No clear or minimal outcome data
Lee 2019 [34] No genetic mitochondrial diagnose
Leung 1998 [35] No genetic mitochondrial diagnose
Liu 2019 [36] Wrong population
Malojcic 2004 [37] No genetic mitochondrial diagnose




Study / Year Reason for exclusion
Martikainen 2012 [39] Low glycemic index diet
Na 2020 [40] No genetic mitochondrial diagnose
Nass 2019 [41] No clear or minimal outcome data
Nathan 2019 [42] Wrong population
Ngoh 2016 [43] Unknown diet composition
Nishioka 2018 [44] No clear or minimal outcome data
Nizon 2014 [45] High fat diet
Nolan 2019 [46] No clear or minimal outcome data
No genetic mitochondrial diagnose
Oonthonpan 2019 [48]
Panetta 2004 [49] Unknown diet composition
Pronicki 2017 [50] Unknown diet composition
Punzi 2008 [51] Unknown diet composition
Salman 2017 [52] Wrong population: Glut 1
Schmid 2019 [53] No genetic mitochondrial diagnose
Seaver 2018 [54] Unknown diet composition
Seo 2010 [55] No genetic mitochondrial diagnose
Soler-Alfonso 2019 [56] Unknown diet composition
Sort 2013 [57] No genetic mitochondrial diagnose
Stowe 2018[58] Unknown diet composition
Storoni 2019 [59] Review, no human cases
Sutton 2010 [60] Wrong population: secondary mitochondrial dysfunction
Taban 2006 [61]
Theunissen 2017 [62] High fat diet
Vasta 2012 [63] No genetic mitochondrial diagnose
Villeneuve 2017 [64] No genetic mitochondrial diagnose
Williams 2012 [65] No clear or minimal outcome data
Yadav 2019 [66] No genetic mitochondrial diagnose
Yamanaka 1987 [67] No genetic mitochondrial diagnose
Yilmaz 2010 [68] No genetic mitochondrial diagnose
Yoon 2014 [69] No genetic mitochondrial diagnose
You 2009 [70] No clear or minimal outcome data
Zhang 2018 [71] No clear or minimal outcome data
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1. To gain knowledge on the nutritional status and its determinants in adult MD patients.
3. To provide evidence for individually tailored nutritional interventions in MD patients.
MAIN FINDINGS
presented in this thesis.
NUTRITIONAL STATUS OF ADULT MD PATIENTS AND ITS 
DETERMINANTS
Chapter 2 focused on identifying symptoms that lead to a decreased BMI and increased 
risk for malnutrition in adult MD patients. Gastrointestinal problems (86%), especially 
very common in carriers of the m.3243A>G mutation. The severity of gastrointestinal 
problems as well as overall disease severity was associated with an increased risk for
malnutrition in the form of a low BMI. There was however no relevant correlation 
between gastrointestinal problems and BMI, indicating that probably other factors 
contribute to the risk of malnutrition.
The results support the hypothesis that severely affected patient have a higher risk for 
malnutrition. Apabhai et al [1] studied a similar MD population in the UK (Newcastle): in 
contrast these authors found that almost half of the patients were overweight, similar to 
healthy controls. While chapter 2
controls. Still around one third of these patients had a BMI>25. Therefore, both under- and 
overweight seems to be a problem in this population. It should be realized here that also 
patients with normal or high BMI may still be at risk for malnutrition because of an inadequate
diet, with altered body composition (low muscle mass and high fat mass) and low functioning.






and functioning. A lower protein intake could not be established in MD patients when 
compared with healthy controls (P = 0.07). However, relative to their protein needs, more 
MD patients had a protein intake that was too low (68%) as compared to healthy controls 
(12%). Two other studies by Hou et al [2] and Aubry et a [3] reported a lower muscle mass
muscle mass compared to reference data but the controls also had a low muscle mass and
therefore any differences between MD patients and controls could not be demonstrated.
work [3]. According to the GLIM criteria, 46% of MD patients were malnourished, whereas 
43% according to the PG-SGA criteria. This seems a consistent result, however, there 
was a low overlap in malnutrition between the two methods. A better comparability was
seen between sarcopenia and malnutrition since all patients diagnosed with sarcopenia
of diagnosing malnutrition and underlines the conclusions of Aubry et al. (2017) [3] that
nutritional assessment should be part of patient care in all adult MD patients.
THE OPTIMAL METHOD FOR NUTRITIONAL ASSESSMENT IN 
ADULT MD PATIENTS
Measurements of Nutritional Assessment should always comprise tree domains:
1. Food intake and requirements
2. Body composition
3. Functional parameters
Chapter 5 focused on domain 1, i.e. energy requirement. The conclusion is that total 
energy expenditure is lower in MD patients compared to the recommendations for 
healthy adults, most probably because of their lower physical activity. In MD patients 
six predictive equations for resting energy expenditure provide a reliable alternative
for Indirect calorimetry, with an accuracy in the range of 71-76%. As Physical Activity 
Levels (PAL) are highly variable and are not reliably estimated by the patients themselves, 
measurement of PAL using accelerometery is recommended in this population.
In chapter 4 the second domain i.e. body composition was evaluated and the diagnostic
accuracy of BIA versus DXA measurements in adult MD was tested. The conclusion was that 
for measuring body composition, DXA should be preferably used instead of BIA because of
the higher accuracy. If DXA is not available, waist circumference is the preferred additional 
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method besides BIA to assess the risk for obesity and metabolic syndrome in this population
In chapter 4 multiple functional tests from the third domain were executed: handgrip
strength, 30 sec sit to stand test, 6 minute walking test and the 6 minute mastication 
test. The choice for these tests were based on the expertise of the physiotherapist of the 
multidisciplinary mitochondrial expertise team from the Radboudumc. In both the GLIM
consensus for diagnoses of malnutrition [4] and in the sarcopenia consensus [5] handgrip
strength is included which is easy to perform by patients, besides also dietitians can include 
this in their consultation with minimal additional effort or costs. The handgrip strength 
test provides valuable data on functioning, however reference values and cutoff points are 
unclear. For instance, in the Sarcopenia consensus cutoff points are used based on data
provided by Dodds et al [6] for 70-year-old patients. This makes sense because sarcopenia 
is mainly a muscle disorder in elderly. However, chronically ill patients, including the MD 
population, frequently suffer from sarcopenia as well [2,7,8]. Since the mean age of the MD 
population is between 40-45 years, it is incorrect to use the cutoff point for 70-year-old
patients without further evidence. In chapter 4 is demonstrated that indeed sarcopenia
gets underdiagnosed when the mentioned consensus cutoff point are used. Therefore, 
In chapter 4
Malnutrition (GLIM) [4] to diagnose malnutrition and sarcopenia consensus to diagnose
sarcopenia [18] were applied to the adult MD population.
The PG-SGA has been validated in oncology patients and it is suggested to be suitable for
other patient categories [10]. The MD patient, however, in contrast to cancer patients in 
found in chapter 6,
in an improved PG-SGA score. This could be explained by the fact that gastrointestinal 
symptoms are frequently seen in MD patients, as described in chapter 2, which comprise
a substantial part of the PG-SGA score. For example, the individual diet intervention 
could decrease the severity of constipation, but the patient still received 1 point for 
PG-SGA score. Moreover the “functioning section” of the PG-SGA contains a question 
about lowering of daily activity which is not suitable for a chronic patient population. 
Apart from these drawbacks, the use of the PG-SGA is supported by the positive fact that 
it is a patient generated instrument that includes all 3 domains of nutritional assessment
and takes little effort to measure. In the Radboudumc the PG-SGA is integrated in the 
The GLIM criteria for malnutrition are categorized into two domains. One is the




criterium. To meet this criterium, patients need to have either a low nutritional intake
of a chronic patient category.
The sarcopenia consensus on the other hand is more suitable for chronic patients, yet 
sarcopenia shows overlap with malnutrition. Also, while both nutrition and mitochondrial 
dysfunction can play a role here [179] sarcopenia is a muscle disorder that mainly occurs
in elderly. Therefore, the consensus only contains two domains: body composition and 
functioning. For sarcopenia diagnosis, body composition (muscle mass) has to be measured
(different from the PG-SGA or GLIM criteria). Although this measurement is more invasive, 
body composition is crucial for the MD patient population because many patients with
normal or even high BMI still have a low muscle mass, which may easily remain undetected 
if not actually measured [3]. In the sarcopenia consensus also functioning has to be
measured, using either hand grip strength or the sit-to-stand tests. As national expertise 
centre for mitochondrial disease, the Radboudumc has experience with both of these non-
invasive tests. The sit to stand test has additional advantages in MD patients because of the 
The results of chapter 4 are in line with the results of Aubry et al [3] who performed
nutritional assessment on al domains in 11 MD patients and 15 controls. These
the European Society of Clinical Nutrition and Metabolism (ESPEN), but none were
malnourished according to the screening tool (nutritional risk score NRS-2002). Thus,
the latter tool seems less sensitive in chronically ill outpatients.
The overall conclusion is that all available tools to diagnose malnutrition in adult MD
patients have their advantages and drawbacks, without one being optimal in this setting. 
Nutritional Assessment of adult MD patients should always comprise the tree domains 
(intake and requirements, body composition and functioning). For energy requirements 
accelerometery is recommended. For body composition DXA is recommended and if 
that is not possible BIA in combination with a waist circumference is considered second
best. For functioning, handgrip strength using age appropriate cutoff points of the Dodds
reference [6] or the sit to stand test, are suitable non-invasive test.
INDIVIDUALLY TAILORED NUTRITIONAL INTERVENTIONS IN 
MD PATIENTS
Part 2 of this thesis focuses on the evidence to support nutritional interventions. The 
conclusion is that an individually tailored dietary intervention is promising to achieve 
personalized goals of patients with MD, especially with regard to body composition,
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handgrip strength and gastrointestinal complaints. The intervention also improves quality 
of life and decreases fatigue on the short term.
recommendations. KD should be considered in individuals with MD and therapy 
refractory epilepsy, while mtDNA deletion(s) related myopathy is a contraindication. 
Ketogenic diet is a highly individual management option in this fragile patient group and
requires an experienced team. To increase knowledge on this -individually- promising




A strength of this thesis is that all research questions were driven from 20 years of
recommendations have been implemented as part of the personalized patientcare in 
the Radboudumc national expertise centre for mitochondrial disease (RCMM).
The possibility to perform these studies with the help of the relatively large patient
population of the RCMM, and especially the genetically homogeneous cohort of 
m.3243A>G carriers, was crucial in this respect.
Another strength of this thesis were the selected study methods. This especially concerns
the matched-control design of the DYNAMO study, in which the gold standard (DXA)
was used to assess body composition. The same applies for the innovative strategy to 
calculate total energy expenditure by means of accelerometery. Finally, the fact that this 
now only case reports were available to guide dietitians practises is of value.
Limitations
The relatively small sample size and the heterogeneity of the patients remain inevitable
limitations. The provision of data on nutritional intake is also a weakness in all studies
because both under- and over-reporting nutritional intakes probably occurred.
Chapter 6 is an explorative randomized controlled trial on individually tailored nutritional
interventions. This was a very challenging study with numerous confounders, ending up 
in a combination between an RCT with 39 subjects and 39 n=1 trials. We strongly believe




provide. For instance, the lack of a gold standard to diagnose malnutrition is a handicap,
since testing all the separate items of nutritional assessment caused statistical issues
related to multiple testing. Despite these limitations, the DINAMITE study yielded many
relevant data and clinical insights.
In chapter 4 the DYNAMO study, has a limitation regarding the validity of the DXA
measurements which may have been affected by the use of 2 scanners on two locations:
Although these scanners were from the same brand, they were different models and
calibration was only possible for bone density, but not for body composition.
IMPLICATIONS AND FUTURE PERSPECTIVES
The nutritional implications and recommendations based on the results of this thesis are 
summarised in Figure 1. This summary was published as a poster on the SSIEM congress 
in Rotterdam 2019 [11].
Research agenda
• A prospective intervention study to investigate whether a higher protein intake 
may improve functioning in MD.
• A RCT with a standardized diet intervention (fodmap diet [12]) in MD patients 
with gastrointestinal complaints.
•
myopathy. This is a pilot study in 20 patients with genetically proven mitochondrial
myopathy started in October 2020.
GENERAL CONCLUSION
Malnutrition is very common in MD, even in patients with a normal or high BMI. 
Unfortunately, usual screening tools lack sensitivity to detect malnutrition in this 
chronically ill patient group. All adult patients with MD should receive full nutritional 
functional parameters. This Nutritional assessment should include adequate interviews 
checking for gastrointestinal complaints, accelerometry, assessment of body composition
(e.g. DXA or BIA with waist circumference) and functional testing (e.g. handgrip strength
measurements and/or 30 second sit to stand test). Nutritional interventions should be 
tailored in a personalized manner and based on the nutritional assessment outcomes. 
Nutritional interventions can be helpful for MD patients to achieve personal goals in 



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1. Summary of nutritional implications and recommendations based on the results of this 
thesis.
1) low energy intake < 90% individual needs = calculated REE + measured PAL (with actometre) 2) 
low protein intake <1,2 gram/kg ideal bodyweight 3) low handgrip according to (Dodds 2014) 4) low 
muscle mass; preferable measured by DXA = SMI < 7 kg/m2 for men and < 5,5 kg/m2 for women or FFMI 
measured by BIA < 15 kg/m2 for women and <17 kg/m2 for men (GLIM criteria 2018) 5) weight loss = 
> 5% in 6 months or > 10% > 6 months (GLIM criteria 2018) 6) low BMI =< 20 kg/m2 (GLIM criteria 
m2 (WHO 2000) 9) high fat percentage =  >30 % for women and >25 % for men (Okorodudu 2010) 10) 
malnutrition = according to GLIM 2018 = low muscle mass4, low BMI6 or weight loss5 + low nutritional 
intake1,2 or malnutrition according to PG SGA 11) sarcopenia= consensus 2018 = low Handgrip Strenght3
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Mitochondrial diseases (MD) are relatively frequently inborn errors of metabolism. MD 
are a clinically and genetically highly heterogeneous set of disorders, characterized by a
disturbed intracellular energy metabolism. Since no curative treatment is available so far, 
the management of MDs remains supportive. As such, dietary interventions are part of 
interventions commonly aim to treat or prevent malnutrition, gastrointestinal problems or
epilepsy. Malnutrition in MD is felt to be common although the true incidence is unclear.
Because of the quite heterogeneous phenotypical character of the MD population recent 
literature suggests to perform nutritional assessment to assess the nutritional state. This
advice is hampered however by the notion that neither the most optimal techniques to 
perform this evaluation nor their actual cutoff values in the setting of MD remain elusive.
on clinical outcome measures in the setting of MD given the small number of patients 
and, again, the heterogeneous nature of the population. We therefore assumed that a
personalized intervention approach in these patients might be more appropriate and 
successful. This thesis aims to improve the knowledge on nutritional status and its
determinants (aim 1), to provide ideas on the optimal strategy of nutritional assessment 
(aim 2) and to bolster the evidence for individually tailored nutritional intervention regimes 
(aim3) and, ultimately, improve the functioning and quality of life of adult MD patients.
Part 1 focuses on Nutritional Assessment in adult MD patients.
Chapter 2 is an observational study that explores and characterizes the frequency and 
severity of gastrointestinal complaints including dysphagia in 92 adult patients carrying 
the m.3243A>G mutation in mitochondrial DNA using a validated questionnaire.
Data were compared with those obtained in healthy controls. This study showed that
dysphagia and gastrointestinal problems, especially constipation, are common symptoms 
in the total m.3243A>G carrier cohort and are not related to heteroplasmy levels in
urinary epithelial cells (UEC), nor to disease severity. The severity of gastrointestinal 
problems as well as overall disease severity is associated with an increased risk for 
malnutrition based on their lower BMI.
Chapter 3 focuses on nutritional intake. In this observational, cross-sectional,
retrospective study, 60 three-day nutrition diaries of adult MD patients were analysed
and compared with the Dutch recommended daily allowance and the Dutch National
Food Consumption Survey. This study demonstrated that patients with MD have an
low. Interindividual differences were found to be high.
Chapter 4 comprises the results of the DYNAMO study. In this two-site cross-sectional




to healthy controls. The results suggest that muscle strength is related to body
composition and protein intake in MD patients. Seventy-three percent of MD patient 
were malnourished according to the GLIM criteria and/or PG-SGA, and 14-27% could 
energy X-ray absorptiometry (DXA).
Chapter 5 aimed to identify the optimal method to estimate total energy expenditure in 
MD patients. Resting energy expenditure was measured in adult MD patients carrying
the m.3243A>G mutation using indirect calorimetry and was compared with results of 21
predictive equations for resting energy expenditure, as well as with indirect calorimetry
data in healthy controls. Physical activity level (PAL) was assessed using accelerometery 
estimated activity levels. Total energy expenditure was lower in MD patients than the
recommendations for healthy adults because of their lower physical activity. In MD patients,
6 prediction equations for resting energy expenditure provided a reliable alternative
for physical activity levels proved not to be a suitable alternative to accelerometery.
Part 2 focuses on Nutritional Interventions in MD patients.
Chapter 6 describes the results of the DINAMITE study. The aim of this randomized
controlled trial was to explore the effect of an individually tailored dietary intervention on
personalized goals, body composition, functioning, and quality of life in 39 adult MD patients
due to the m.3243A>G mutation. The intervention group (n = 20) received an individually
tailored dietary intervention over a 6-month period, whereas controls (n = 19) received 
standard care during 6-months (control period), followed by an individually tailored
dietary intervention for the next 6 months (intervention period). Nutritional assessment
and QoL measurements were performed at 3-month intervals. After 3 months of dietary
intervention, 57% of the personalized goals were achieved. Most successfully realized
goals were improved body composition, handgrip strength, and diminished gastrointestinal
complaints. Consistent effects on functioning included improved handgrip strength,
vitality, and fatigue score. These effects, however, did not seem to last after 3 months.
Chapter 7
of KD for MD is too scarce for general recommendations. KD should be considered
in individuals with MD and therapy refractory epilepsy, while it is contraindicated in
mitochondrial DNA deletion(s) related myopathy. When considering KD for MD the high
rate of adverse effects should be taken into account, but also spectacular improvements 
in individual cases. KD is a highly individual management option in this fragile patient
group and requires an experienced team. To increase knowledge on this -individually- 




A general discussion and suggestions for future research are described in Chapter 8.
In conclusion, malnutrition is very common in MD, even in patients with a normal or
high BMI. Unfortunately, usual screening tools lack sensitivity to detect malnutrition in
this chronically ill patient group. All adult patients with MD should receive full nutritional
functional parameters. This Nutritional assessment should include adequate interviews 
checking for gastrointestinal complaints, accelerometry, assessment of body composition 
(e.g. DXA or BIA with waist circumference) and functional testing (e.g. handgrip strength 
measurements and/or 30 second sit to stand test). Nutritional interventions should be 
tailored in a personalized manner and based on the nutritional assessment outcomes.
Nutritional interventions can be helpful for MD patients to achieve personal goals in





Mitochondriële ziekten (MZ) zijn relatief frequente voorkomende aangeboren
stofwisselingsstoornissen. MZ zijn klinisch en genetisch zeer heterogene aandoeningen, 
die allemaal worden gekenmerkt door een verstoord energiemetabolisme. Aangezien er
geen curatieve behandeling beschikbaar is, is de behandeling van MZ ondersteunend.
Dieetinterventies vormen hier een belangrijk onderdeel van. Het bewijs voor deze 
dieetinterventies is echter schaars. De dieetinterventies bij MZ zijn veelal gericht op
het voorkomen van ondervoeding, maag-darm klachten of epilepsie. Ondervoeding komt 
vaak voor bij MZ, maar hoe vaak precies is onduidelijk. Vanwege het zeer heterogene
karakter van de MZ-patiëntenpopulatie wordt in de recente literatuur aanbevolen om 
Nutritional Assessment (het systematisch beoordelen van de voedingstoestand en 
voedingsbehoefte) uit te voeren om de voedingstoestand te bepalen. De meest optimale
Nutritional Assessment technieken, noch hun afkapwaarden voor MZ zijn bekend.
Het is moeilijk om wetenschappelijk bewijs te leveren voor positieve effecten van een 
interventie bij MZ vanwege het kleine aantal patiënten en de heterogene aard van de 
populatie. Daarom is een gepersonaliseerde interventie wellicht geschikter. Het doel van
de studies in dit proefschrift is om de kennis over de voedingsstatus en de determinanten
ervan (doel 1), de optimale strategie voor Nutritional Assessment (doel 2) en het bewijs 
voor individueel op maat gemaakte dieetinterventies (doel 3) te verbeteren en daarmee 
het functioneren en de kwaliteit van leven bij volwassen MZ-patiënten te verbeteren.
Deel 1 richt zich op Nutritional Assessment bij volwassen MZ-patiënten.
Hoofdstuk 2 is een observationele studie waarin de frequentie en ernst van maag-darm
klachten bij 92 volwassen patiënten met de m.3243A>G-mutatie werd onderzocht
met behulp van een gevalideerde vragenlijst. De gegevens werden vergeleken met 
die van gezonde controles. De resultaten tonen aan dat slikklachten en maag-darm 
problemen, vooral obstipatie, veel voorkomende symptomen zijn in het totale cohort 
van m.3243A>G-dragers en dat het voorkomen van deze klachten niet gerelateerd 
is aan heteroplasmie percentages of de ernst van de ziekte. De ernst van maag-darm 
problemen en de algehele ernst van de ziekte waren geassocieerd met een verhoogd 
risico op ondervoeding op basis van een lagere BMI.
Hoofdstuk 3 richt zich op de voedingsinname. In deze observationele, cross-sectionele, 
retrospectieve studie werden zestig driedaagse voedingsdagboeken van volwassen 
MZ-patiënten geanalyseerd en vergeleken met de Nederlandse aanbevolen dagelijkse 
hoeveelheid en de Nederlandse Nationale Voedselconsumptiepeiling. Deze studie toonde
aan dat patiënten met MZ een inadequate intake hebben. Met name de inname van eiwitten, 
calcium, zuivelproducten en vloeistoffen was laag en de onderlinge verschillen waren groot.
Hoofdstuk 4 beschrijft de resultaten van de DYNAMO studie. In deze cross-sectionele 
studie met deelnemers van twee centra, werden genetisch bewezen volwassen
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MZ-patiënten gematched met gezonde controles op basis van leeftijd, body mass
index en geslacht. Dit onderzoek toonde aan dat spierkracht gerelateerd is aan de 
lichaamssamenstelling en eiwitinname bij MZ-patiënten. 73% van de MZ-patiënten was 
massa in vergelijking met DXA.
Hoofdstuk 5
energieverbruik bij MZ-patiënten te schatten. Het energieverbruik in rust werd gemeten
bij volwassen MZ-patiënten met de m.3243A>G-mutatie met behulp van indirecte 
calorimetrie en vergeleken met resultaten van 21 voorspellende vergelijkingen voor 
energieverbruik in rust, evenals met indirecte calorimetrie gegevens van gezonde
controles. Het fysieke activiteitsniveau (PAL) werd beoordeeld met behulp van de
actometer (SenseWear®) en vergeleken met een vaste gemiddelde PAL en met het zelf
geschatte activiteitsniveau van de patiënt. Het totale energieverbruik was lager bij MZ-
patiënten dan de aanbevelingen voor gezonde volwassenen vanwege hun lagere fysieke 
activiteit. Bij MZ-patiënten boden 6 voorspellingsvergelijkingen voor energieverbruik in 
rust een betrouwbaar alternatief voor indirecte calorimetrie, met een nauwkeurigheid
van 71% -76%. De eigen schattingen van de patiënten voor fysieke activiteitsniveau 
bleken geen geschikt alternatief voor actometrie.
Deel 2 richt zich op voedingsinterventies bij MZ-patiënten.
Hoofdstuk 6 beschrijft de resultaten van de DINAMITE studie. Het doel van deze
gerandomiseerde gecontroleerde studie was om het effect te onderzoeken van een 
individueel op maat gemaakte voedingsinterventie op gepersonaliseerde doelen,
lichaamssamenstelling, functioneren en kwaliteit van leven bij 39 volwassen MZ-
patiënten als gevolg van de m.3243 A>G-mutatie. De interventiegroep (n = 20) kreeg
een dieetinterventie op maat over een periode van 6 maanden, terwijl de controlegroep
(n = 19) gedurende 6 maanden standaardzorg kreeg (controleperiode), gevolgd door een 
dieetinterventie op maat voor de volgende periode van 6 maanden (interventieperiode). 
Nutritional Assessment en kwaliteit van leven metingen werden uitgevoerd met 
tussenpozen van 3 maanden. Na 3 maanden voedingsinterventie werd 57% van de 
persoonlijke doelen bereikt. De meest effectieve doelen waren lichaamssamenstelling, 
handknijpkracht en maagdarmklachten. Een consistent effect op het functioneren werd
aangetoond voor handknijpkracht, vitaliteit en vermoeidheidsscore, maar deze effecten 
hielden niet aan na 3 maanden.
Hoofdstuk 7 geeft een systematisch overzicht van de effecten en bijwerkingen van
het ketogeen dieet (KD) bij genetisch bewezen MZ-patiënten (zowel kinderen als
volwassenen). Gegevens over de effectiviteit en veiligheid van KD voor MZ zijn te
schaars voor algemene aanbevelingen. KD kan worden overwogen bij personen met
MD en therapieresistente epilepsie, terwijl mitochondriale DNA-deletie(s) gerelateerde 




rekening worden gehouden met het hoge aantal bijwerkingen, maar ook met spectaculaire 
verbeteringen in individuele gevallen. KD is een zeer individuele behandeloptie en vereist 
een ervaren team. Om de kennis over deze -individueel- veelbelovende managementoptie 
te vergroten, zijn meer (prospectieve) onderzoeken met adequate uitkomstmaten
noodzakelijk.
Een algemene discussie en suggesties voor toekomstig onderzoek zijn te vinden in 
hoofdstuk 8.
Concluderend: ondervoeding komt veel voor bij MZ, zelfs bij patiënten met een normale
of hoge BMI, en de gebruikelijke screeningsinstrumenten zijn onvoldoende gevoelig
voor het detecteren van ondervoeding bij deze chronisch zieke patiëntengroep. Alle 
volwassen patiënten met MZ moeten een volledige nutritional assessment krijgen van
3) functionele parameters. Dit nutritional assessment moet interviews waarin maag-
darmklachten worden nagevraagd, accelerometrie, meting van lichaamssamenstelling 
en functionele testen (bijv. handknijpkracht of een zit-sta-test) bevatten. 
Voedingsinterventies moeten op een gepersonaliseerde manier worden afgestemd 
en gebaseerd op de resultaten van nutritional assessment. Op deze manier kunnen
voedingsinterventies voor MZ-patiënten nuttig zijn om persoonlijke doelen op het gebied 




Toen ik aan dit promotietraject begon, hebben velen mij gewaarschuwd dat het geen 
gemakkelijke weg zou zijn en veel vrije tijd zou kosten. Ze hebben gelijk gehad, maar ik ben
zo blij dat ik het gedaan heb en ik ben trots op het eindresultaat. Ik heb vaak gezegd dat 
onderzoek doen mijn hobby was en nu heb ik van mijn hobby, mijn werk kunnen maken. 
Er waren veel mensen die in me geloofden en die me gesteund hebben. Ik ben blij dat ik 
jullie hiervoor nu kan bedanken. Dit boekje is het resultaat van veel samenwerken en ik 
heb daarvan genoten. Ik voel me gezegend dat ik met zoveel lieve, getalenteerde mensen
heb mogen werken. Zonder jullie was het nooit gelukt en ik wil iedereen die dit leest
enorm bedanken voor hun bijdrage. In dit dankwoord wil ik van de gelegenheid gebruik
maken om een persoonlijk woord te richten tot een aantal van u.
Allereerst wil ik de patiënten en gezonde proefpersonen erg bedanken voor hun 
medewerking aan mijn onderzoeken. Ik ben erg onder de indruk van de deelnemers aan 
mijn studies. Zij moesten veel tests ondergaan, lijsten invullen en diëten volgen en deden
dat zonder klagen. Dank jullie wel!
Beste Mirian Janssen. Ik ben jou het meeste dankbaar van iedereen. Je bent gewoon
samenwerken. Ik voelde me in 2010 toen ik naar de volwassen metabole ziekten overkwam
direct enorm welkom. We zitten op één lijn in hoe we over patiënten bejegening en eigen
verantwoordelijkheid denken. We geloven allebei erg in de persoonsgerichte patiëntenzorg 
mensen elkaar steunen en verder helpen. Ik ben dankbaar dat dat in ons team zo is.
Beste Geert Wanten. Ik heb het echt getroffen met mijn beide copromotoren. Jij bent 
echt een arts met passie voor je vak. Tijdens onze afspraken over het onderzoek had
je altijd wel een verhaal over een patiënt die je op dat moment zag. Ik ben je vooral erg
dankbaar voor je correcties van mijn vele taal- en grammaticafouten in de artikelen.
Ik kan zelf nog niet geloven dat juist ik een boekje geschreven heb. Dit was dan ook echt
niet mogelijk geweest zonder mensen zoals jij die, met eindeloos geduld, al mijn stukken
begeleidende mail de opbeurende woorden: “paar kleine wijzigingen”. Jij, en ook Mirian, 
hebben mij vrijgelaten in het bedenken van de studies die ik wilde doen. Jullie gaven mij
de juiste onderzoeksopzet etcetera.
Beste Prof. dr. Joost Drenth, als promotor heeft u mij de kans gegeven dit onderzoek te 
doen en me volledig vrijgelaten bij de invulling hiervan. U heeft me het vertrouwen gegeven 




de dinsdagbijeenkomsten met de andere PhD studenten van de MDL afdeling. Ik heb me
welkom gevoeld in deze groep, ondanks dat ik toch echt wel een vreemde eend in de bijt was.
Ik wil dan ook graag mijn mede promovendi bedanken voor hun vele tips en waardevolle 
feedback. Ik wil ook de statistici verbonden aan MDL bedanken: Wietske, Femke,
Reinier en Wiebe erg bedankt voor jullie hulp bij de statistiek.
Ik wil graag de leden van de manuscriptcommissie (prof. dr. P. J. van der Wees, Prof. dr.
C. D.M. van Karnebeek en Prof. dr. ir P.J.M. Weijs) bedanken voor hun deelname aan 
deze commissie en het beoordelen van dit proefschrift.
Lieve Sanne en Thea, Jullie zijn mijn paranimfen. Een erebaan die jullie echt verdienen.
Sanne
ons metabole team te hebben. Jij houdt niet zo van onderzoek, maar hebt veel andere 
talenten waardoor we elkaar perfect aanvullen in het team dat nu, met Karlijn erbij, alleen
nog maar sterker en gezelliger is geworden. Jij hebt mijn hele manuscript aan het eind nog
aan een gedetailleerde correctieronde onderworpen terwijl je het zelf superdruk had op
nierziekten. Typisch Sanne! Jij staat altijd voor iedereen klaar, dank je wel!
Thea mijn lieve creatieve zusje. Als ik soms de neiging had harder te werken dan gezond 
voor me was, dan zorgde jij voor de ontspanning. Ik geniet altijd enorm van de activiteiten
die we samen ondernemen of het nu de Marikenloop is, de Libelle zomerweek of 
ontworpen. Dank je wel daarvoor, ik vind het erg mooi geworden.
van de afdeling Diëtetiek en Darmfalen, dank jullie wel voor de goede 
Renske, wij 
piet in maatje 164 op ons eerste coronaproef team uitje. Annemiek, ik geniet van onze 
samenwerking op het ketogeen- en actometerproject. Renee, Karlijn en Sanne, het is zo 
vakkundig. Manon, dank je wel voor al je goede werk. Mede dankzij jou heeft onderzoek 
binnen onze afdeling een duidelijke plaats gekregen. Hetzelfde geld voor Marjo, jij hebt 
onze afdeling naar een hoger niveau getild en geknokt voor de positie die we nu hebben.
Jij hebt mij gestimuleerd me te ontwikkelen en ik heb me daardoor erg gesteund gevoeld. 
Dank je wel daarvoor! Ook de secretaresses Ria en Rachel wil ik bedanken voor hun 
geweldige ondersteuning. Yudith, onze carrières vertonen veel overeenkomsten, dat 
maakt dat ik me met jou verbonden voel.
onze overleggen: De voorbespreking van de poli met Alexander, Mirian en Elke en de
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Leo, Marleen en Karlien) en het MDO van de mitostraat 
met Simone, Daphne, Nanette, Jan, Elke en de patiënt. Wij vullen elkaar perfect 
aan. De mitostraat zorgt voor veel werkplezier en is een perfect voorbeeld van hoe
gepersonaliseerde zorg in een expertisecentrum georganiseerd kan worden. Ik ben ook 
dankbaar en trots dat alle aanbevelingen in dit boekje in de mitostraat geïmplementeerd 
 Maaike, Lonneke en Marion bij jullie ben ik 
begonnen en we delen de passie voor dit prachtige specialisme. Jullie voelen nog steeds als
nu nog steeds mag begeleiden in hun volwassen leven. In mijn werk als gespecialiseerd 
metabool diëtist is, mede door mijn interesse in onderzoek, de samenwerking met 
Neurologie ook steeds belangrijker geworden. Vooral met Christiaan Saris en Nicole 
Voermans werk ik tegenwoordig heel plezierig samen. Met Nicole werk ik samen op het
gebied van FSHD en McArdle. Met Christiaan werk ik aan de KETOMY-studie. Christiaan
heeft het initiatief genomen voor deze boeiende studie waar zeker nog een vervolg op komt.
Prof dr. Baziel van Engelen, u stond aan het begin van dit promotie traject. U nodigde 
mij uit op uw kantoor en vroeg of ik niet wilde overwegen om promotieonderzoek te 
doen. Mirian reageerde gelijk enthousiast, zij had daar ook al aan zitten denken. In het
begin hebben wij drieën een aantal afspraken gehad en daarmee is dit onderzoekstraject 
gestart. Ik ben u hier heel dankbaar voor.
Nog verder terug was er Prof Dr. Eva Morava, zij is degene die mij enthousiast gemaakt
heeft voor wetenschap. Zij vond het heel normaal dat diëtisten onderzoek deden in een 
tijd dat dit binnen onze afdeling nog niet zo gebruikelijk was. Zij stimuleerde het, nam me
mee op congres en liet me mee publiceren.
MODAZ, Corrie, Jorien, Monique, Ageeth, Liesbeth, Elles, 
Marit, Silvia, Susanne, Marloes, Adorée, Iris, Foekje, Esther, Lisa, Leonie en Merel
Karen, Jade, An, Ulrike en Laura. Ik geniet enorm 
van de MODAZ bijeenkomsten want jullie enthousiasme geeft me energie. Met veel van 
jullie ben ik op congres geweest in mooie Europese steden. Daarvoor wil ik ook graag 
de sponsoren van de industrie bedanken die dit mogelijk hebben gemaakt: 
Nutricia Liesbeth, jij bent
de voorzitter van het MODAZ (dat nu eigenlijk DIES heet) en onze stabiele factor. Jij 
moet het daar in Maastricht allemaal in je eentje doen en dan vind je ook nog altijd tijd 
om onze kar te trekken. Je hebt nooit gemopperd als je weer eens als eerste op moest 
en als laatste thuis was vanwege de reisafstand naar onze meetings. Corrie onze (oud)
secretaris van de SSIEM-DG, ik ben supertrots op jou, je reageert altijd supersnel op 
MODAZ-mails en springt op de bres voor de volwassen metabole patiënten. Wij hebben
samen het artikel geschreven over afvallen bij vetzuuroxidatiestoornissen. Dat was een




Eiffeltoren gestaan, jammer dat je de metabole ziekten hebt verlaten en last but not least
Greet, jij bent mijn grote voorbeeld.
te pakken, ik ben zo trots op wat we al bereikt hebben samen. Hinke,
jij ook lid bent geworden van het NAP. Jouw enorme kennis en ervaring met het zakboek
en je link met het NTVD heeft enorm bijgedragen aan het bereiken van onze doelen. 
Susanne Leij, wij hebben samen het NAP opgericht en hoewel je nu zelf geen lid meer 
bent, ben ik je hiervoor enorm dankbaar. Onze samenwerking in de koppelstructuur was 
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